

Smith ScholarWorks

**Biological Sciences: Faculty Publications** 

**Biological Sciences** 

7-8-1998

# Thermoregulation of *Escherichia coil pap* Transcription: H-NS is a Temperature-Dependent DNA Methylation Blocking Factor

Christine A. White-Ziegler University of Utah Health Sciences, cwhitezi@smith.edu

Melinda L. Angus Hill University of Utah Health Sciences

Bruce A. Braaten University of Utah Health Sciences

Marjan W. Van Der Woude University of Utah Health Sciences

David A. Low University of Utah Health Sciences

Follow this and additional works at: https://scholarworks.smith.edu/bio\_facpubs

Part of the Biology Commons

#### **Recommended Citation**

White-Ziegler, Christine A.; Angus Hill, Melinda L.; Braaten, Bruce A.; Van Der Woude, Marjan W.; and Low, David A., "Thermoregulation of *Escherichia coil pap* Transcription: H-NS is a Temperature-Dependent DNA Methylation Blocking Factor" (1998). Biological Sciences: Faculty Publications, Smith College, Northampton, MA.

https://scholarworks.smith.edu/bio\_facpubs/247

This Article has been accepted for inclusion in Biological Sciences: Faculty Publications by an authorized administrator of Smith ScholarWorks. For more information, please contact scholarworks@smith.edu

### Thermoregulation of *Escherichia coli pap* transcription: H-NS is a temperature-dependent DNA methylation blocking factor

#### Christine A. White-Ziegler,<sup>†</sup> Melinda L. Angus Hill, Bruce A. Braaten, Marjan W. van der Woude<sup>‡</sup> and David A. Low<sup>\*</sup>

Division of Cell Biology and Immunology, Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA.

#### Summary

The expression of Pap pili that facilitate the attachment of Escherichia coli to uroepithelial cells is shut off outside the host at temperatures below 26°C. Ribonuclease protection analysis showed that this thermoregulatory response was rapid as evidenced by the absence of papBA transcripts, coding for Pap pilin, after only one generation of growth at 23°C. The histone-like nucleoid structuring protein H-NS and DNA sequences within papB were required for thermoregulation, but the PapB and PapI regulatory proteins were not. In vivo analysis of pap DNA methylation patterns indicated that H-NS or a factor regulated by H-NS bound within the pap regulatory region at 23°C but not at 37°C, as evidenced by H-NS-dependent inhibition of methylation of the pap GATC sites designated GATC-I and GATC-II. These GATC sites lie upstream of the papBAp promoter and have been shown previously to play a role in controlling Pap pili expression by regulating the binding of Lrp, a global regulator that is essential for activating papBAp transcription. Competitive electrophoretic mobility shift analysis showed that H-NS bound specifically to a pap DNA fragment containing the GATC-I and GATC-II sites. Moreover, H-NS blocked methylation of these pap GATC sites in vitro: H-NS blocked pap GATC methylation at 1.4 µM but was unable to do so at higher concentrations at which non-specific binding occurred. Thus, non-specific binding of H-NS to pap DNA was not sufficient to inhibit methylation of the pap GATC

© 1998 Blackwell Science Ltd

sites. These results suggest that the ability of H-NS to act as a methylation blocking factor is dependent upon the formation of a specific complex of H-NS with *pap* regulatory DNA. We hypothesize that a function of H-NS such as oligomerization was altered at 23°C, which enabled H-NS to repress *pap* gene expression through the formation of a specific nucleoprotein complex.

#### Introduction

Pap pili, encoded by the pyelonephritis-associated pili (pap) operon, are expressed by uropathogenic Escherichia coli and play a critical role in the colonization of host tissues in upper urinary tract infections (Hagberg et al., 1983; Lindberg et al., 1984; Roberts et al., 1989). At 37°C, the expression of Pap pili is subject to a phase variation control mechanism. Within a population of bacteria, some of the cells express pili (phase ON), while others cells do not (phase OFF) (Low et al., 1987; Blyn et al., 1989; van der Woude et al., 1996). At temperatures below 26°C, Pap pili expression is shut off (Göransson and Uhlin, 1984; White-Ziegler et al., 1990). This type of thermoregulatory response has been shown to control virulence factor expression in many bacterial genera including Escherichia (Roosendaal et al., 1986; Jordi et al., 1992), Shigella (Maurelli et al., 1984), Bordetella (Coote, 1991), Yersinia (Cornelis et al., 1989) and Listeria (Leimeister et al., 1992). Presumably, bacteria sense temperature and other environmental signals to determine whether they are inside or outside of a host. Low temperature may thus serve as an environmental cue to the bacterium that it is outside of a host. The subsequent shutoff of pili expression would allow the bacterium to conserve its resources by preventing the synthesis of protein structures that are needed only within a host and may be deleterious in non-host environments.

Thermoregulation of Pap pili expression occurs at the transcriptional level (Göransson and Uhlin, 1984; Blyn *et al.*, 1989; White-Ziegler and Low, 1992) Using a single-copy *papBAp–lacZ* operon fusion in which the  $\beta$ -galactosidase gene is placed under the control of the *papBAp* promoter, we have shown that the expression of *papBA* mRNA, encoding the regulatory protein PapB and the main pilus structural protein PapA, is subject to both

Received 14 November, 1997; revised 6 March, 1998; accepted 12 March, 1998. Present addresses: †Department of Biological Sciences, Smith College, Northhampton, MA 01063, USA; ‡Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6076, USA. \*For correspondence. E-mail Low@medschool.med.utah.edu; Tel. (801) 581 4901; Fax (801) 581 4517.



**Fig. 1.** The *pap* regulatory region and operon fusion constructs. The *papIBA* regulatory region is shown at the top with the basepair numbering system used in this study. The small open circles around GATC-I represent Lrp DNA binding sites 4, 5 and 6, whereas the small, closed circles around GATC-II represent Lrp binding sites 1, 2 and 3 (Nou *et al.*, 1995). The wild-type *papBAp* fusion and *pap* mutant constructs are shown in the expanded scale below the *pap* regulatory region. The designations for each mutant construct are shown at the right (see Table 1). The *papIp* operon fusion is shown at the bottom.

phase variation and thermoregulatory control mechanisms (Blyn *et al.*, 1989). At 37°C, both Lac<sup>+</sup> (phase ON) and Lac<sup>-</sup> (phase OFF) colony phenotypes were observed as a result of phase variation. Lac<sup>+</sup> colonies arose from cells that were phase ON and expressed *papBA–lacZ* mRNA, while Lac<sup>-</sup> colonies arose from cells that were phase OFF and did not express *papBA–lacZ* mRNA. In contrast, at 23°C, only Lac<sup>-</sup> phase OFF colonies were observed, indicating that *papBA–lacZ* transcription was shut off at low temperature (Blyn *et al.*, 1989; White-Ziegler and Low, 1992).

Although the mechanism by which thermoregulation of Pap pili expression occurs is not known, genetic analyses have indicated that the global regulator H-NS plays an essential role (Göransson *et al.*, 1990). H-NS is a 15.5 kDa global regulatory protein that represses the transcription of many environmentally regulated operons in *E. coli* and other enteric bacteria (Ussery *et al.*, 1994). The work described above with H-NS (Göransson *et al.*, 1989a; 1990) was carried out using multicopy plasmid-encoded

pap sequences, which abolish the Pap pili phase variation that is observed at 37°C in single-copy wild-type uropathogenic E. coli (Low et al., 1987; Blyn et al., 1989). Under multicopy pap conditions, the normal regulatory circuit involving leucine-responsive regulatory protein (Lrp), the pap-encoded co-regulatory protein Papl and deoxyadenosine methyltransferase (Dam) is disrupted (van der Woude et al., 1992). Pap phase variation is controlled by the differential methylation of two DNA GATC sites within the pap regulatory region (Braaten et al., 1994). The two GATC sites are targets for methylation by Dam (Blyn et al., 1990). The GATC-II site is located 53 bp upstream of the papBA transcription start site, whereas the GATC-I site is 102 bp upstream of GATC-II (Fig. 1). In phase OFF cells, the GATC-I site is methylated, and the GATC-II site is non-methylated, whereas the converse pattern is found in phase ON cells (Blyn et al., 1990). Lrp is a global regulator in E. coli that activates some genes and represses others (Calvo and Matthews, 1994), and Lrp is required to block Dam methylation of both pap GATC sites (Braaten

et al., 1991; Nou et al., 1993). In Pap phase OFF cells, Lrp binds co-operatively to three sites (designated as sites 1, 2 and 3) in the pap regulatory DNA and blocks methylation of the GATC-II site, which is located within Lrp site 2 (Fig. 1; Nou et al., 1995). Binding of Lrp at sites 1, 2 and 3 inhibits pap transcription, presumably because of steric hindrance of RNA polymerase to the papBAp promoter that lies between Lrp sites 2 and 3. The GATC-I site is methylated by Dam, as Lrp is not bound in this region in phase OFF cells (Braaten et al., 1994; Nou et al., 1995). Methylation of GATC-I reduces the affinity of Lrp for pap DNA sites 4 and 5 (Nou et al., 1993). As binding of Lrp to pap sites 4 and 5 is necessary for papBA transcription activation (Nou et al., 1995), we hypothesized that methylation of GATC-I locks cells in the phase OFF state until DNA replication occurs (Braaten et al., 1994).

In phase ON cells, the GATC-I site is non-methylated, whereas the GATC-II site is methylated (Blyn *et al.*, 1990). The PapI protein, along with Lrp, is necessary for blocking methylation of the GATC-I site (Braaten *et al.*, 1991). PapI binds to Lrp and increases its affinity for *pap* Lrp binding sites 4 and 5 at the GATC-I region (Nou *et al.*, 1995). This shift in Lrp binding protects the GATC-I site from methylation, freeing the GATC-II site to be methylated by Dam. By this mechanism, Lrp can act as both a repressor and an activator of *papBA* transcription (Nou *et al.*, 1995; van der Woude *et al.*, 1995). Lrp activates transcription when bound at the GATC-I site, whereas Lrp bound at the GATC-II site blocks transcription.

Additional regulatory proteins, including PapB and cAMP receptor protein (CRP), also play important roles in Pap phase variation. PapB activates *papI* transcription (Båga *et al.*, 1985) by binding to the *pap* regulatory region upstream of the *papIp* promoter (Forsman *et al.*, 1989). Pap phase variation occurs in *papB*<sup>-</sup> cells under conditions in which PapI is constitutively expressed (see *Results*), showing that PapB plays an indirect role in activating *pap* transcription. CRP binds 215.5 bp upstream of the *papIp* transcription (Göransson *et al.*, 1989b) Recent data indicate that CRP is not required for translocation of Lrp to sites 4, 5 and 6 but plays a role at a later step (unpublished data).

In this study, we investigated the roles of PapI, PapB, H-NS and *pap* regulatory DNA sequences in Pap thermoregulation. These experiments were carried out under conditions in which a *papBAp–lacZ* fusion was present in single copy on the chromosome and Pap phase variation occurred (Low *et al.*, 1987). Results showed that H-NS as well as DNA sequences within or near *papB* were required for thermoregulation of transcription at *papBAp*, but PapI and PapB were not. *In vivo* methylation analysis indicated that H-NS or an H-NS-regulated factor blocked methylation of the *pap* GATC sites at 23°C but not at 37°C. *In*  *vitro* analyses at 23°C showed that H-NS bound specifically to the *pap* regulatory region and blocked methylation of the *pap* GATC-I and GATC-II sites. We hypothesize that an important step in the thermoregulation of Pap pili expression is the temperature-dependent formation of a specific H-NS–*pap* nucleoprotein complex.

#### Results

## The relationship between Papl levels and thermoregulation

Previous results obtained using multicopy plasmid-encoded pap indicated that papl transcription as well as Pap pili expression was reduced at low temperature. Additionally, overproduction of PapI caused a loss of thermoregulation as evidenced by expression of Pap pili at 26°C (Göransson et al., 1989a). From these observations, it was hypothesized that thermoregulation of papBA transcription was an indirect effect caused by limiting amounts of Papl at low temperature. To determine if these observations were also true under conditions in which phase variation of Pap pili expression occurred, we carried out experiments using a single-copy, chromosomal paplp-lacZ transcriptional fusion (Fig. 1), which placed *lacZ* under the control of the paplp promoter (E. coli DL2838, Table 1). This E. coli isolate showed phase variation at 37°C with switch rates similar to those measured previously for the papBAp promoter (Table 2). At 23°C, all E. coli DL2838 colonies had a Lac<sup>-</sup> colony phenotype. We measured a 14-fold reduction in β-galactosidase activity at 23°C (15 Miller units) compared with 37°C (213 Miller units), demonstrating that papl transcription was thermoregulated.

To assess the relationship between PapI levels and thermoregulation of *papBA* transcription quantitatively, we analysed *E. coli* containing a single-copy *papBAp*–*lacZ* fusion (DL1504, Table 1). This *E. coli* isolate switched reversibly between phase OFF and ON states at 37°C (Table 2). At 23°C, all colonies of strain DL1504 displayed a phase OFF Lac<sup>-</sup> phenotype resulting from the loss of transcription of the *papBA* genes at low temperature (Table 3). Analysis of  $\beta$ -galactosidase levels showed that *papBA* expression was reduced 52-fold at 23°C compared with expression at 37°C (Table 3).

PapI levels in *E. coli* DL1504 were modulated by the introduction of plasmid pDAL262, which contains the *papI* gene under the control of the *lac* promoter (Table 1), and plasmid pPY1025 expressing the Lacl<sup>q</sup> repressor (Braaten *et al.*, 1994). Regulation of PapI levels in the resulting DL2223 transformant could then be modulated by the addition of IPTG. Even in the absence of IPTG, PapI was overexpressed in DL2223 based on immunoblot analysis (data not shown) and an increase in the  $\beta$ -galactosidase level at 37°C (2250 units, Fig. 2A) relative to the DL1504 parent strain lacking pDAL262 (1082 units, Table 3). Unlike

#### 1124 C. A. White-Ziegler et al.

**Table 1.** Bacterial strains, bacteriophages and<br/>plasmids used in this study.

EcolirecA1 endA1 [F' laclq ZM/15 Tr10 (Tet') Amy Cari]Stratagene Amy Cari]DL379MC4100 A246 (syogen MC4100 A354 1syogen DL1505Biyn et al. (1989)DL1505MC4100 A354 (syogen DL1742Braaten et al. (1994)DL1744MC4100 Al/p VanderWoude et al. (1985)DL1744MC4100 Al/p VanderWoude et al. (1985)DL1940DL1506 Ins651 DL1945DL1945DL1506 Ins651 MC4100 A354-15 (syogen DL2220DL1954MC4100 A354-51 (syogen DL2220DL2208MC4100 A354-51 (syogen DL2225DL2754UT5600 containing pDAL461 DL2774DL2755MC4100 A354-51 (syogen DL2275DL2754UT5600 containing pDAL468 DL2771DL2260MC4100 A354-73 (syogen DL2275DL2261MC4100 A354-73 (syogen DL2276DL2275MC4100 A354-73 (syogen DL2276DL2365MC4100 A354-73 (syogen DL2365DL2365MC4100 A354-73 (syogen DL2365DL365MC4100 A354-73 (syogen DL3654DL365MC4100 A354-73 (syogen DL3654DL365MC4100 A354-73 (syolgen DL3654DL365MC4100 A354-73 (syolgen containing pDAL468 DL3371This studyDL2365MC4100 A354-73 (syolgen DL3647DL362MC4100 A354-73 (syolgen DL36478DL364MC4100 A354-73 (syolgen DL36478DH3717Staff combinant phage This studyPhage A354 Phage A354NH757B178/hns61 (syr/157710FlaseFlase et al. (1980)Phage A354 <th>Strain, plasmid or phage</th> <th>Description (relevant genotype)</th> <th>Reference or source</th>	Strain, plasmid or phage	Description (relevant genotype)	Reference or source
E. coliStratageneXL-2 BluerecAt endAt [F' laclq ZAM15 Tr10 (Tef')StratageneAmy Cam]MC4100.326 (sysogenBiyn et al. (1986)DL1505MC4100.335-1 (sysogen papa)Braaten et al. (1994)DL1742MC4100.335-1 (sysogen papa)This studyDL1744MC4100.336-1 (sysogen papa)This studyDL1744MC4100.336-1 (sysogen papa)This studyDL1744MC4100.336-1 (sysogen papa)This studyDL1805DL1505 AlrpvanderWoude et al. (1995)DL1945DL1506 AlrpvanderWoude et al. (1995)DL1945DL1506 Ans651This studyDL2208MC4100.336-15 (sysogen This studyDL2275MC4100.336-16 (sysogen This studyDL2775DL2006 containing pDAL468This studyDL2775DL2006 containing pDAL468This studyDL2773DL2208 containing pDAL468This studyDL305MC4100.336-73 (sysogen containing pDAL469This studyDL305MC4100FaaraD139 D[aclPO2YA-argF]/UF89Casadaban (1976)Phage A36-1NR4545-DAL397 recombinant phageThis studyPhage A36-1NR4545-DAL397 recombinant phageThis studyPhage A36-1NR4545-DAL397 recombinant phageThis study<			
DL379MC4100MC410	<i>E. coli</i> XL-2 Blue	recA1 endA1 [F' laclq Z∆M15 Tn10 (Tet <sup>r</sup> )	Stratagene
DL:150Initial (1994)DL:150MC4100 A354 lysogenBraaten et al. (1994)DL:1505MC4100 A354 lysogen papelBraaten et al. (1994)DL:1742MC4100 A354 lysogen papelThis studyDL:1744MC4100 AlpvandetWoude et al. (1985)DL:1910DL:1506 Inse67vandetWoude et al. (1985)DL:1944DL:1506 Inse67This studyDL:1950DL:1506 Inse67This studyDL:2223MC4100 A354-51 lysogenThis studyDL:2230MC4100 A354-59 lysogenThis studyDL:2754U15600 containing pDAL468This studyDL:2754U15600 containing pDAL468This studyDL:2754DL:2756 containing pDAL468This studyDL:2755MC4100 A354-73 lysogenThis studyDL:283MC4100 A354-73 lysogenThis studyDL:283MC4100 A354-73 lysogenThis studyDL:3056MC4100 A354-73 lysogenThis studyDL:284MC4100 A354-73 lysogenThis studyPL:284MC4100 A354-73 lysogenThis studyPHage A354XR45+DAL374 recombinant phageThis studyPhage A354XR45+DAL374 recombinant phageThis studyPhage A354XR45+DAL374 recombinant	DI 270	Arriy Carri J MC4100 ) 246 lysogon	Rlyp at al. (1080)
Li LibbInc H (10 X354-1 hysogen (1984)Dialacti et al. (1984)Li LibbMC4100 X354-1 hysogen $d_{papl}$ This studyLi T742MC4100 X354-1 hysogen $d_{papl}$ VanderWoude et al. (1995)Li T84MC4100 hns651vanderWoude et al. (1995)Li 1810DL 1504 $Alp$ vanderWoude et al. (1995)Li 1848DL 1910 hns651vanderWoude et al. (1995)Li 1848DL 1910 hns651vanderWoude et al. (1995)DL 2020MC4100 hns651This studyDL 2203DL 1504 containing pDAL262, PY1025This studyDL 2755MC4100 X354-59 hysogenThis studyDL 2774DL 2008 containing pDAL488This studyDL 2775DL 1504 containing pDAL486This studyDL 2774DL 2775 containing pDAL486This studyDL 2775DL 1504 containing pDAL488This studyDL 2008 containing pDAL488This studyDL 2036MC4100 X354-73 hysogenThis studyDL 3056MC4100 X354-73 hysogenThis studyPhage X354hX845-pDAL354 recombinant phageThis studyPhage X354hX845-pDAL354-15 containing phageThis studyPhage X354hX845-pDAL354-15 corombinant phageThis studyPhage X354hX	DL379		Broaten et al. $(1909)$
Dick	DL 1504	MC4100 X354 Tysogen	Braaten et al. $(1994)$
Li 1742Incl 100 JulyIns audyDi 1784MC4100 JulyVanderWoude et al. (1995)Di 1504 JulyVanderWoude et al. (1995)Di 1504 JulyDi 1505 Ams657VanderWoude et al. (1995)VanderWoude et al. (1995)Di 1505 Mos657This studyDi 1506 MC4100 AS54-15 (soggenThis studyDi 2208 MC4100 AS54-59 (soggenThis studyDi 2755 MC4100 AS54-59 (soggenThis studyDi 2773 DL 2208 containing pDAL468This studyDi 2773 DL 2208 containing pDAL468This studyDi 2774 DL 2755 containing pDAL468This studyDi 2775 DL 1504 containing pDAL468This studyDi 2775 DL 2008 containing pDAL468This studyDi 2005 MC4100 A354-73 (soggen containing pDAL468This studyDi 2005 MC4100 A354-73 (soggen containing pDAL689This studyDi 2006 MC4100 A354-73 (soggen containing pDAL680This studyDi 2006 MC4100 A354-73 (soggen containing pDAL680This studyDi 2006 MC4100 AS4-73 (soggen containing pDAL680This studyDi 2006 MC4100 AS4-73 (soggen containing pDAL680This studyPhage R845 IaCZYA imm <sup>21</sup> Simons et al. (1987)Phage A354 AR545-pDAL354 recombinant phageThis studyPhage A354 AR545-pDAL354 recombinant phageThis studyPhage A354 AR545-pDAL354-15 recombinant phageThis studyPhage A354 AR	DL1303	MC4100 X354-1 lysogen Apap/	This study
DisplayValue in Carlos JupValue in Carlos JupDisplayDisplayValue in Carlos JupDisplayDisplayDisplayDisplayDisplayDisplayDisplayDisplayDisplayDisplayDisplayDisplay <tr< td=""><td>DL1742 DL1794</td><td></td><td>vanderWoude et al. (1995)</td></tr<>	DL1742 DL1794		vanderWoude et al. (1995)
Display Display Display Display Display Display Display Display Display Display 	DL1704	DI 1504 Alm	vanderWoude et al. (1995)
DL1344   DL1304 Intabl   Value in Value is al. (1993)     DL1345   DL1505 Inta657   This study     DL1305   MC4100 A354-15 lysogen   This study     DL2223   DL1506 containing pDAL262, PY1025   This study     DL2754   UT5600 containing pDAL268, PY1025   This study     DL2774   UL2755 containing pDAL468   This study     DL2774   DL2755 containing pDAL468   This study     DL2774   DL2755 containing pDAL468   This study     DL3056   MC4100 A354-73 lysogen   This study     DL3056   MC4100 A354-73 lysopen containing pDAL468   This study     DL3056   MC4100 A354-73 lysopen containing pDAL468   This study     DL3056   MC4100 A354-73 lysopen containing pDAL468   This study     DH3757   B178/na85611/718::Tn10   Falconi et al. (1991)     UT5600   Jac2YA imm <sup>21</sup> Simons et al. (1993)     Phage A354-1   NR545-pDAL354 recombinant phage   This study     Phage A	DL 1910	$DL1504 \Delta llp$	vanderWoude et al. (1995)
DL1865   DL1905 hns057   This study     DL208   DL1505 hns057   This study     DL208   MC4100 hns057   This study     DL208   MC4100 A354-15 lysogen   This study     DL2755   MC4100 A354-59 lysogen   This study     DL2771   DL1504 containing pDAL488   This study     DL2773   DL208 containing pDAL488   This study     DL2774   DL2750 containing pDAL488   This study     DL3052   MC4100 A354-73 lysogen   This study     DL3056   MC4100 A354-73 lysogen   This study     DL3057   ML82 lacl/acl? org/1 Aleu trpE thi-1 AlepA-omp7   Rupprecht et al. (1981)     VT550   JL822 lacl   RAS45-pDAL354 recombinant phage   Brasten et al. (1984)     Phage X354   XR345-pDAL354 recombinant phage   This study   This study     Phage X354-15   XR345-pDAL354 recombinant phage   This study   This study     Phage X354-15   XR345-pDAL354 recombinant phage   This study </td <td>DL 1947</td> <td>DI 1910 bns651</td> <td>vanderWoude et al. (1995)</td>	DL 1947	DI 1910 bns651	vanderWoude et al. (1995)
Dit 1900Dit 1900This studyDit 2000MC4100 hns657This studyDit 2228MC4100 hns657This studyDit 2228Dit 504 containing pDAL481This studyDit 22754UT5600 containing pDAL481This studyDit 2774Dit 2000 holds of the studyThis studyDit 2775Dit 2000 holds of the studyThis studyDit 2774Dit 2755 containing pDAL468This studyDit 2775Dit 2000 holds of the studyThis studyDit 2000 holds of the studyThis studyPhage	DI 1965	DI 1505 bns651	This study
Display=200MC4100 0.354-15 lysogenThis studyDisplay=200Display=200This s	DI 1976	MC4100 bps651	This study
Display <td>DL 2208</td> <td>MC4100 354-15 lysogen</td> <td>This study</td>	DL 2208	MC4100 354-15 lysogen	This study
DL2754UT5600 containing pDAL481This studyDL2755MC4100 $\lambda$ 354-59 lysogenThis studyDL2771DL1504 containing pDAL468This studyDL2773DL2208 containing pDAL468This studyDL2774DL2755 containing pDAL468This studyDL2774DL2755 containing pDAL468This studyDL3052MC4100 $\lambda$ 354-73 lysogen containing pDAL468This studyDL3056MC4100 $\lambda$ 354-73 lysogen containing pDAL468This studyDL3057MC4100 $\lambda$ 354-73 lysogen containing pDAL468This studyDL3056MC4100 $\lambda$ 354-73 lysogen containing pDAL468This studyDL3057MC4100 $\lambda$ 354-73 lysogen containing pDAL468This studyDL3058MC4100 $\lambda$ 54-73 lysogen containing pDAL469RistodyB1758nx651tyrTp::Tn10Falconi et al. (1991)UT5600JlacZ lacl <sup>2</sup> omp7 Jleu trpE thi-1 $\Delta$ 16pA-omp7BacteriophagesPhage $\lambda$ 354-1NR45-pDAL354 recombinant phagePhage $\lambda$ 354-1NR45-pDAL354-1 recombinant phageBraaten et al. (1987)Phage $\lambda$ 354-59NR545-pDAL354-19 recombinant phageThis studyPhage $\lambda$ 354-59NR545-pDAL354-19 recombinant phageThis studyPhage $\lambda$ 364-73NR545-pDAL364 recombinant phageThis studyPhage $\lambda$ 364-73NR545-pDAL364 recombinant phageThis studyPhage $\lambda$ 364-59NR545-pDAL364 recombinant phageThis studyPhage $\lambda$ 364-59NR545-pDAL364Recombinant phageThis studyPhage $\lambda$ 374-59NR555-pDAL379Recombinant phageThis study <td>DI 2223</td> <td>DI 1504 containing pDAI 262 pPY1025</td> <td>This study</td>	DI 2223	DI 1504 containing pDAI 262 pPY1025	This study
DL2756MC4100 N364-69 lysogenThis studyDL2771DL208 containing pDAL468This studyDL2773DL2208 containing pDAL468This studyDL2774DL2755 containing pDAL468This studyDL2838MC4100 A941 lysogenThis studyDL3056MC4100 A364-73 lysogen containing pDAL468This studyDL3056MC4100 A364-73 lysogen containing pDAL468This studyDL3056MC4100 A364-73 lysogen containing pDAL468This studyDL3057MC4100 A364-73 lysogen containing pDAL468This studyDL3058MC4100 A364-73 lysogen containing pDAL469This studyDL3059MC4100 A364-73 lysogen containing pDAL469This studyDL3050MC4100 A364-73 lysogen containing pDAL469This studyD13051MC4100 A364-73 lysogen containing pDAL469This studyD13052MC4100 A364-73 lysogen containing pDAL469This studyD17500Alac2 Lad" omp J Lieu trpE thi-1 <i>AtepA-ompT</i> Falconi et al. (1991)BacteriophagesIac2YA imm <sup>21</sup> Simons et al. (1987)Phage A354NR545-pDAL354 recombinant phageThis studyPhage A354-1NR545-pDAL354-73 recombinant phageThis studyPhage A364-59NR545-pDAL354-73 recombinant phageThis studyPhage A364-73NR545-pDAL364 recombinant phageThis studyPhage A364-73NR545-pDAL364 recombinant phageThis studyPhage A364-73NR545-pDAL364 recombinant phageThis studyPhage A364-73NR545-pDAL364 repal/B DNABlyn et al. (1993)	DI 2754	UT5600 containing pDAI 481	This study
DL2771DL1504 containing pDAL488This studyDL2773DL208 containing pDAL488This studyDL274DL2755 containing pDAL488This studyDL3052MC4100 $\lambda$ 54.73 lysogenThis studyDL3056MC4100 $\lambda$ 54.73 lysogen containing pDAL488This studyDL3057MC4100 $\lambda$ 54.73 lysogen containing pDAL488This studyDL3056MC4100 $\lambda$ 54.73 lysogen containing pDAL488This studyDL3077NL72B lue containing pDAL589This studyCasadaban (1976) <i>prst.th:1</i> This studyNT757B178bns651rtyTB::Tn10Falconi et al. (1991)BacteriophagesInacZ lacl <sup>2</sup> omp7 $\Delta$ leu trpE thi-1 $\Delta$ fepA-omp7Rupprecht et al. (1983)Phage $\lambda$ 544\R545-pDAL374 recombinant phageBir atten et al. (1994)Phage $\lambda$ 544\R545-pDAL354 recombinant phageBir atten et al. (1994)Phage $\lambda$ 545\R545-pDAL354-15 recombinant phageThis studyPhage $\lambda$ 544\R545-pDAL354-15 recombinant phageThis studyPhage $\lambda$ 354-15\R545-pDAL354-15 recombinant phageThis studyPhage $\lambda$ 364-59\R555-pDAL364-91 recombinant phageThis studyPhage $\lambda$ 374-13\R545-pDAL364-19 recombinant phageThis studyPhage $\lambda$ 374-14\Virulent phage P1L. CaroPhage $\lambda$ 374-15\R545-pDAL364-91Rochara-1Phage $\lambda$ 374-14\Virulent phage P1L. CaroPhage $\lambda$ 374-15\R555-pDAL374Rester-phala91Phage $\lambda$ 374-15\R556-pDAL364-91Rester-phala91Phage $\lambda$ 374-16	DI 2755	MC4100 $\lambda$ 354-59 lysogen	This study
DL2773     DL220e containing pDAL488     This study       DL2774     DL2755 containing pDAL488     This study       DL3056     MC4100 \3454-73 lysogen     This study       DL3057     MC4100 \354-73 lysogen containing pDAL488     This study       DL3056     MC4100 \354-73 lysogen containing pDAL488     This study       DL3077     TL22Blue containing pDAL468     This study       DL307     TL22Blue containing pDAL468     This study       DL307     B178hns6571yr7B: Tn10     Falconi et al. (1991)       T15600     Llac2YA imm <sup>21</sup> Simons et al. (1987)       Phage RS45     Iac2YA imm <sup>21</sup> Simons et al. (1984)       Phage X354     NR545-pDAL354-1 recombinant phage     This study       Phage X354-1     NR545-pDAL354-15 recombinant phage     This study       Phage X354-3     NR545-pDAL354-15 recombinant phage     This study       Phage X354-3     NR545-pDAL354-73 recombinant phage     This study       Phage X354-73     NR545-pDAL354-73 recombinant phage     This study       Phage X354-73     NR545-pDAL354-73 recombinant phage     This study       Phage Y14     Virulent phage P1     Lic C	DL2771	DL1504 containing pDAL468	This study
DL2774 DL288DL2755 containing pDAL468 DL3052This study This study This studyDL3052 DL3056MC4100 \394-73 lysogen organThis study This studyDL3056 MC4100 \7354-73 lysogen organThis study This studyDL3057 MC4100 PSL_thi-1This study This studyNH757 D15600B178hns651tyrTB: Th10 Jac2 lacl <sup>6</sup> ompT Jeleu trpE thi-1 \depA-ompTFalconi et al. (1991)NH757 Drage \226 Phage \2364I7845-pDAL354 recombinant phage Braaten et al. (1987)Biyn et al. (1987)Phage \2364 Phage \2364-b\RS45-pDAL354 recombinant phage Braaten et al. (1994)Biyn et al. (1984)Phage \2364-b\RS45-pDAL354 recombinant phage Phage \2364-bThis studyPhage \2364-b\RS45-pDAL354 recombinant phage Braaten et al. (1994)Phage \2364-b\RS45-pDAL354-73 recombinant phage Phage \2364-f3This studyPhage \2364-f3 Phage \2364-f3\RS45-pDAL354-73 recombinant phage Phage \2364-f3This studyPhage \2364-f3 Phage \2365-f3\RS45-pDAL354-73 recombinant phage Phage \2364-f3This studyPhage \2364-f3\RS45-pDAL354-73 recombinant phage Phage \2364-f3This studyPhage \2464 Phage \2464\RS45-pDAL364-91 recombinant phage Phage \2364-f3This studyPhage \2364-f3\RS45-pDAL364-91 recombinant phage Phage \2364-f3This studyPhage \2464 Phage \2465 Phage \2465\RS45-pDAL364-91 recombinant phage Phage \2464This studyPhage \2464 Phage \2465 Phage \2465 Phage \2465\RS45-pDAL364Recomp Phage \24	DL2773	DL2208 containing pDAL468	This study
DL2828   MC4100 λ391 lysögen   This study     DL3052   MC4100 λ354-73 lysogen containing pDAL468   This study     DL3056   MC4100 λ354-73 lysogen containing pDAL468   This study     DL317   XL-2 Blue containing pDAL569   This study     MC4100   F <sup>-</sup> araD139 D(24PC2YA-argF)U169   Casadaban (1976)     NH757   B17Bhns65ftyrTB::Tn10   Falconi et al. (1981)     W15600   AlacZ lacl <sup>q</sup> ompT Aleu trpE thi-1 ΔfepA-ompT   Rupprecht et al. (1983)     Bacteriophages   Phage λ854   IRACYA imm <sup>21</sup> Simons et al. (1987)     Phage λ854   NRS45-pDAL354-1 recombinant phage   Braaten et al. (1994)     Phage λ354-1   λRS45-pDAL354-15 recombinant phage   This study     Phage λ354-3   λRS45-pDAL354-73 recombinant phage   This study     Phage λ354-3   λRS45-pDAL354-73 recombinant phage   This study     Phage λ354-73   λRS45-pDAL35	DL2774	DL2755 containing pDAL468	This study
DL3052MC4100 X354-73 lysogenThis studyDL3056MC4100 X354-73 lysogen containing pDAL569This studyMC4100F <sup>-</sup> araD139 D(lac/POZYA-argF)U169Casadaban (1976)rpsL.thi-1rpsL.thi-1Falconi et al. (1991)NH757B178hns651 tryTB::Tn10Falconi et al. (1983)BacteriophagesPhage X845lacZYA imm <sup>21</sup> Phage X845lacZYA imm <sup>21</sup> Simons et al. (1987)Phage X354XR545-pDAL354 recombinant phageBraaten et al. (1984)Phage X354XR545-pDAL354 recombinant phageBraaten et al. (1994)Phage X354-15XR545-pDAL354-15 recombinant phageThis studyPhage X354-59XR545-pDAL354-73 leccombinant phageThis studyPhage X354-51XR545-pDAL354-73 leccombinant phageThis studyPhage X354-73XR545-pDAL354-73 leccombinant phageThis studyPhage X354-73XR545-pDAL354-73 leccombinant phageThis studyPhage X354-73XR545-pDAL354-73 leccombinant phageThis studyPhage P1L4Virulent phage P1L. CaroPlasmid5geunceChang (1978)pDAL262pT218R containing a 271 bp <i>papl</i> DNANou et al. (1989)pAL264pRS551 containing 1.6kb <i>pap/B</i> DNABiyn et al. (1994)pDAL354pDAL354 with GATC <sup>1028</sup> site changedBraaten et al. (1994)pDAL354pDAL354 with ATG start codon of <i>papB</i> This studypDAL354-73pAD4-lac2)DNA sequencepDAL354pDAL354 with a 503 bp <i>papB</i> /intergenicThis studypDAL354 with GATC <sup>1028</sup>	DL2838	MC4100 λ491 lysogen	This study
DL3056MC4100 $\lambda$ S4-73 (so gen containing pDAL468This studyDL3317XL-2 Blue containing pDAL569This studyMC4100F <sup>-</sup> araD139 D[(aclPO2YA-argF)U169Casadaban (1976)npsL thi-1FileFileNH757B178hns651tyrTB::Tn10Falconi et al. (1991)BacteriophagesJacZ lacl <sup>q</sup> ompT Jleu trpE thi-1 $\Delta$ fepA-ompTRupprecht et al. (1987)Phage AS45JacZYA imm <sup>21</sup> Simons et al. (1987)Phage AS45 $\lambda$ RS45-pDAL354-1 recombinant phageBraaten et al. (1994)Phage A354-1 $\lambda$ RS45-pDAL354-15 recombinant phageThis studyPhage A354-59 $\lambda$ RS45-pDAL354-15 recombinant phageThis studyPhage A354-59 $\lambda$ RS45-pDAL354-73 recombinant phageThis studyPhage A354-73 $\lambda$ RS45-pDAL354-73 recombinant phageThis studyPhage A354-73 $\lambda$ RS45-pDAL354-73 recombinant phageThis studyPhage A354 $\lambda$ RS45-pDAL354-73 recombinant phageThis studyPhage P1L4Virulent phage P1L. CaroPlasmidspUH22 PzI-2ColE11 replicon containing the Plac/ara-1 promoter)Lutz and Bujard (1997pAL262pTZ18R containing 1.76 kb <i>papI</i> DNA sequence (AB1))Blyn et al. (1984)pAL337pT219U containing a 1.76 kb <i>papI</i> BNA sequence (aBAD-acZ)Braaten et al. (1994)pAL354-15pDAL354 with GATC <sup>1028</sup> site changed to GCTCThis studypDAL354pAS550 containing a 271 bp <i>papI</i> This studypDAL354-73pDAL354 with GATC <sup>1028</sup> site changed thanged to CTG (B15)This studypD	DL3052	MC4100 λ354-73 lysogen	This study
DL3317XL-2 Blue containing pDAL569This studyMC4100F <sup>-</sup> araD139 D(lac/POZYA-argF)U169Casadaban (1976)ppst. thi-1FI3bns651tyrTB::Tn10Falconi et al. (1991)NH757B17Bhns651tyrTB::Tn10Falconi et al. (1983)BacteriophagesPhage ARS45IacZYA imm <sup>21</sup> Simons et al. (1987)Phage A264ARS45-pDAL379 recombinant phageBlyn et al. (1987)Phage A354XRS45-pDAL374 recombinant phageBraaten et al. (1984)Phage A354-15KRS45-pDAL354-16 recombinant phageThis studyPhage A354-16KRS45-pDAL354-59 recombinant phageThis studyPhage A354-17KRS45-pDAL354-59 recombinant phageThis studyPhage A354-18KRS45-pDAL354-59 recombinant phageThis studyPhage A354-73KRS45-pDAL354-59 recombinant phageThis studyPhage A34-73KRS45-pDAL354-59 recombinant phageThis studyPhage A34-73KRS45-pDAL354-59 recombinant phageThis studyPhage A491XRS45-pDAL354-59 recombinant phageThis studyPhage P124Virulent phage P1L. CaroPlasmidsputter promoter)promoter)pACYC184cam-tet p15A repliconChang (1978)pDAL262pTZ18R containing 1.6 kb pap/B DNABiyn et al. (1994)sequencecatlaba 1.76 kb pap/BBraaten et al. (1994)regulatory sequencecatlaba with ATG start codon of pap8This studypDAL354pDAL354 with ATG start codon of pap8This studypDAL354-15pDAL354 with ATG start codon of pap8 <td< td=""><td>DL3056</td><td>MC4100 λ354-73 lysogen containing pDAL468</td><td>This study</td></td<>	DL3056	MC4100 λ354-73 lysogen containing pDAL468	This study
MC4100 $F^- araD139 D(laclPOZYA-argF)U169$ Casadaban (1976)NH757B178bns651tyr7B::Tn10Falconi et al. (1991)NH757AlacZ lacl® ompT Aleu trpE thi-1 $\Delta$ fepA-ompTRupprecht et al. (1983)BacteriophagesPhage ARS45lacZYA imm <sup>21</sup> Simons et al. (1987)Phage ARS45acZYA imm <sup>21</sup> Simons et al. (1987)Phage AS54NRS45-pDAL354 recombinant phageBraaten et al. (1994)Phage AS54-15ARS45-pDAL354-17 ecombinant phageBraaten et al. (1994)Phage AS54-59NRS45-pDAL354-59 recombinant phageThis studyPhage AS54-73NRS45-pDAL354-59 recombinant phageThis studyPhage AS4-73NRS45-pDAL354-73 recombinant phageThis studyPhage AS4-74NRS45-pDAL354-73 recombinant phageThis studyPhage P1L4Virulent phage P1Luz and Bujard (1997)pOCYC184cam-tet p15A repliconChang (1978)pDAL262pTZ18R containing a 271 bp papl DNABuy et al. (1989)sequencepABA-JacZBraaten et al. (1994)pAL337pTZ19U containing 1.6kb pap/BBraaten et al. (1994)pAL354pRS550 containing 1.76kb pap/BBraaten et al. (1994)pDAL354pDAL354 with ATG start codon of papBThis studypDAL354pDAL354 with AGN2 hapd/B DNABraaten et al. (1994)pDAL354-73pDAL354 with AGN2 hapd/B DNABraaten et al. (1994)pDAL354-73pDAL354 with AGN2 hapd/B DNABraaten et al. (1994)pDAL354-73pDAL354 with AGN3 hapd/B DNABraaten et al. (1994)pDAL354-	DL3317	XL-2 Blue containing pDAL569	This study
NH757Bit 78 hns 65 ftyr TB:: Tn10 $AlacZ lacl" amp T Aleu trpE thi-1 \Delta lepA-omp TFalconi et al. (1991)BacteriophagesIacZYA imm21Simons et al. (1987)Phage ARS45lacZYA imm21Simons et al. (1987)Phage ARS45\lambdaRS45-pDAL379 recombinant phageByn et al. (1989)Phage AS54NRS45-pDAL354-17 recombinant phageBraaten et al. (1994)Phage AS54-15NRS45-pDAL354-17 recombinant phageBraaten et al. (1994)Phage AS54-59NRS45-pDAL354-15 recombinant phageThis studyPhage AS4-59NRS45-pDAL354-59 recombinant phageThis studyPhage AS4-73NRS45-pDAL354-73 recombinant phageThis studyPhage AS4-74Virulent phage P1L. CaroPlasmidspUHE2 P2-2ColE1 replicon containing the Plac/ara-1promoter)Lutz and Bujard (1997pACYC184cam-tet p15A repliconChang (1978)pDAL262pTZ18R containing a 271 bp papl DNAsequence (aB11)Nou et al. (1993)pDAL263pRS551 containing 1.76 kb paplBBraaten et al. (1994)pDAL354pRS550 containing 1.76 kb paplBBraaten et al. (1994)pDAL354pRS550 containing 1.76 kb paplBBraaten et al. (1994)pDAL354pRS550 containing a 271 bp paplThis studypDAL354pRS550 containing a papl frameshiftmutationThis studypDAL354pRS550 containing a papl frameshiftmutationThis studypDAL354pRS551 containing a 271 bp paplThis studypDAL354pRS551 containing a 271 bp paplThis study$	MC4100	F <sup>-</sup> araD139 D(laclPOZYA-argF)U169 rosL thi-1	Casadaban (1976)
UT5600 $\Delta lacZ lacl^6 ompT \Delta leu trpE thi-1 \Delta fepA-ompT$ Rupprecht et al. (1983)Bacteriophages $lacZ VA imm^{21}$ Simons et al. (1987)Phage $\lambda$ R545 $\lambda$ R545-pDAL379 recombinant phageBiyn et al. (1987)Phage $\lambda$ 254 $\lambda$ R545-pDAL354 recombinant phageBraaten et al. (1994)Phage $\lambda$ 254-1 $\lambda$ R545-pDAL354-15 recombinant phageThis studyPhage $\lambda$ 254-73 $\lambda$ R545-pDAL354-15 recombinant phageThis studyPhage $\lambda$ 254-73 $\lambda$ R545-pDAL354-73 recombinant phageThis studyPhage $\lambda$ 264 $\lambda$ R545-pDAL354-73 recombinant phageThis studyPhage $\lambda$ 264 $\lambda$ R545-pDAL354-73 recombinant phageThis studyPhage $\lambda$ 264 $\lambda$ R545-pDAL364-73 recombinant phageThis studyPhage $\lambda$ 271 $\lambda$ R545-pDAL364-73 recombinant phageThis studyPhage $\lambda$ 272ColE1 replicon containing the $P_{lac/ara-1}$ promoter)Lutz and Bujard (1997pACYC184cam-tet p15A repliconChang (1978)pDAL262pTZ18R containing 1.6 kb <i>papl</i> DNABiyn et al. (1989)sequence $\lambda$ 273pDAL354pDAL354with GATC <sup>1028</sup> site changedBraaten et al. (1994)regulatory sequencepAL354Braaten et al. (1994)pDAL354-73pDAL354 with ATG start codon of <i>papB</i> This studypDAL354-74pDAL354 with a 503 bp <i>papl</i> IntergenicThis studypDAL354-75pDAL354 with a 503 bp <i>papl</i> IntergenicThis studypDAL354-75pDAL354 with a 503 bp <i>papl</i> IntergenicThis studypDAL354-75pDAL354 with a 503 bp <i>papl</i>	NH757	B178hns651tvrTB. $Tn10$	Falconi <i>et al.</i> (1991)
BacteriophagesInterpretent curveInterpretent curvePhage X246 $\lambda$ RS45-pDAL379 recombinant phageBiyn <i>et al.</i> (1987)Phage X246 $\lambda$ RS45-pDAL354 recombinant phageBiyn <i>et al.</i> (1987)Phage X354-11 $\lambda$ RS45-pDAL354-15 recombinant phageBraaten <i>et al.</i> (1994)Phage X354-53 $\lambda$ RS45-pDAL354-15 recombinant phageThis studyPhage X354-54 $\lambda$ RS45-pDAL354-59 recombinant phageThis studyPhage X354-53 $\lambda$ RS45-pDAL354-75 recombinant phageThis studyPhage A354-73 $\lambda$ RS45-pDAL364-73 recombinant phageThis studyPhage A91 $\lambda$ RS45-pDAL491 recombinant phageThis studyplasmidspUHE2 PzI-2ColE1 replicon containing the P <sub>lac/ara-1</sub> promoterLutz and Bujard (1997pAL262pTZ18R containing a 1.76 kb <i>papl</i> DNA sequence (AB1))Blyn <i>et al.</i> (1989)pDAL37pTZ19U containing a 1.76 kb <i>paplB</i> regulatory sequenceBraaten <i>et al.</i> (1994)pDAL354pRS550 containing 1.76 kb <i>paplB</i> DNABraaten <i>et al.</i> (1994)pDAL354-15pDAL354 with ATG start codon of <i>papB</i> changed to CTG (B15)This studypDAL354-73pDAL354 with ATG start codon of <i>papB</i> changed to CTG (B15)This studypDAL354-73pDAL354 with a 503 bp <i>papB/i</i> ntergenic DNA sequenceThis studypDAL354-74pDAL354 containing a 271 bp <i>pap1</i> <td>UT5600</td> <td>AlacZ lacl<sup>q</sup> ompT Aleu trpE thi-1 AfepA-ompT</td> <td>Rupprecht <i>et al.</i> (1983)</td>	UT5600	AlacZ lacl <sup>q</sup> ompT Aleu trpE thi-1 AfepA-ompT	Rupprecht <i>et al.</i> (1983)
Bacteriophages Phage RX845   acZYA imm <sup>21</sup> Simons et al. (1987) Phage RX845   acZYA imm <sup>21</sup> Simons et al. (1987) Phage A354 A RX845-pDAL354 recombinant phage Braaten et al. (1994) Phage A354-1 RX845-pDAL354-15 ecombinant phage Braaten et al. (1994) Phage A354-53 ARS45-pDAL354-15 ecombinant phage This study Phage A354-73 ARS45-pDAL354-73 recombinant phage This study Phage A354-73 ARS45-pDAL354-73 recombinant phage This study Phage A34-17 ARS45-pDAL364-73 recombinant phage This study Phage A34-17 ARS45-pDAL491 recombinant phage This study Phage A341 ARS45-pDAL491 recombinant phage This study Phage P1L4 Virulent phage P1 L. Caro Plasmids pUHE2 PzI-2 ColE1 replicon containing the P <sub>lac/ara-1</sub> Lutz and Bujard (1997 promoter) pACYC184 cam-tet p15A replicon Chang (1978) pDAL262 pTZ18R containing a 271 bp papI DNA Nou et al. (1993) sequence (AB1)) pDAL364 pRS551 containing 1.6 kb papIB DNA Blyn et al. (1989 regulatory sequence pDAL354 pRS550 containing 1.76 kb papIB DNA Blyn et al. (1994) regulatory sequence (AB1)) pDAL354 with ATG start codon of papB pDAL354-1 pDAL354 with ATG start codon of papB pDAL354-1 pDAL354 with ATG start codon of papB pDAL354-1 pDAL354 with ATG start codon of papB pDAL354-73 pDAL354 with ATG start codon of papB pDAL354-79 pDAL354 with papI papI			
Phage XRS45 <i>Iac2 YA imm</i> Simons <i>et al.</i> (1987)Phage X354 $\lambda$ RS45-pDAL354 recombinant phageBin of al. (1987)Phage X354 $\lambda$ RS45-pDAL354-1 recombinant phageBraaten <i>et al.</i> (1994)Phage X354-15 $\lambda$ RS45-pDAL354-15 recombinant phageThis studyPhage X354-59 $\lambda$ RS45-pDAL354-51 recombinant phageThis studyPhage X354-73 $\lambda$ RS45-pDAL354-73 recombinant phageThis studyPhage X354-73 $\lambda$ RS45-pDAL354-73 recombinant phageThis studyPhage X354-73 $\lambda$ RS45-pDAL354-73 recombinant phageThis studyPhage X354 $\lambda$ RS45-pDAL364-73 recombinant phageThis studyPhage X354 $\lambda$ RS45-pDAL364 $\lambda$ RS45-pDAL364pDAL262pTZ18R containing 1.6 kb <i>papI</i> DNABlyn <i>et al.</i> (1993)sequence (\DeltaB1))pT219U containing 1.76 kb <i>papIB</i> Braaten <i>et al.</i> (1994)pDAL354 $\lambda$ RS45-pDAL354 with GS17 rords site changedBraaten <i>et al.</i> (1994)pDAL354 with GCTC $\lambda$ RS45-pDAL354 with ATG start codon of <i>papB</i> This studypDAL354-73 $pDAL354$ with ATG start codon of <i>papB</i> This studypDAL354-73 $pDAL354$ wit	Bacteriophages	21	
Phage λ246AKS45-pDAL379 recombinant phageBlyn et al. (1989)Phage λ354λRS45-pDAL354 recombinant phageBraaten et al. (1994)Phage λ354-1λRS45-pDAL354-1 recombinant phageThis studyPhage λ354-51λRS45-pDAL354-51 recombinant phageThis studyPhage λ354-53λRS45-pDAL354-51 recombinant phageThis studyPhage λ354-73λRS45-pDAL354-57 recombinant phageThis studyPhage λ354-73λRS45-pDAL354-73 recombinant phageThis studyPhage λ354-73λRS45-pDAL354-73 recombinant phageThis studyPhage λ491λRS45-pDAL37 recombinant phageThis studyPhage λ491λRS45-pDAL37 recombinant phageThis studyPhage λ491λRS45-pDAL37 recombinant phageThis studyPhage λ491λRS45-pDAL37 recombinant phageThis studyPhage λ491λRS45-pDAL364 recombinant phageThis studyPhage λ491λRS45-pDAL37 recombinant phageThis studyPhage λ491λRS45-pDAL364 recombinant phageThis studyphal262pTZ18R containing a 271 bp papl DNANou et al. (1993)pDAL354pRS551 containing 1.76 kb paplBBraaten et al. (1994)regulatory sequence (AB1)sequence (AB10)Braaten et al. (1994)pDAL354pDAL354 with GATC <sup>1028</sup> site changedBraaten et al. (1994)sequence (AB10)pDAL354 with ATG start codon of papBThis studypDAL354-59pDAL354 with ATG start codon of papBThis studypDAL354-73pDAL354 with ATG start codon of papBThis studypDAL354	Phage ARS45	laczya imm <sup>2</sup>	Simons et al. (1987)
Phage A354ARS45-pDAL354-I recombinant phageBraaten <i>et al.</i> (1994)Phage A354-1NRS45-pDAL354-15 recombinant phageThis studyPhage A354-73NRS45-pDAL354-73 recombinant phageThis studyPhage A354-73NRS45-pDAL354-73 recombinant phageThis studyPhage A354-73NRS45-pDAL354-73 recombinant phageThis studyPhage A354-73NRS45-pDAL354-73 recombinant phageThis studyPhage A354-73NRS45-pDAL391 recombinant phageThis studyPhage A354-73NRS45-pDAL491 recombinant phageThis studyPhage A354-73NRS45-pDAL491 recombinant phageThis studyPhage A354-73NRS45-pDAL391 recombinant phageThis studyPlasmidspUHE2 P21-2Collar philos pape P1L. CaroPlasmidspT218P containing a 271 bp papI DNABlyn et al. (1993)sequence (B11)pDAL354pDAL354 with GATC <sup>1028</sup> site changedBraaten et al. (1994)pDAL354-11pDAL354 with GATC <sup>1028</sup> site changedBraaten et al. (1994)to GCTCpDAL354 with a 503 bp papB/intergenicThis studypDAL354-73pDAL354 containing a 271 bp papIThis studypDAL354-73pDAL354 containing a 271 bp papIThis studypDAL354-73pDAL354 containing a 271 bp papIThi	Phage X246	ARS45-pDAL379 recombinant phage	Blyn <i>et al.</i> (1989)
Phage A354-15ARS45-pDAL354-17 recombinant phageBraaten <i>et al.</i> (1994)Phage A354-59ARS45-pDAL354-59 recombinant phageThis studyPhage A354-59ARS45-pDAL354-73 recombinant phageThis studyPhage A354-73ARS45-pDAL354-73 recombinant phageThis studyPhage A491ARS45-pDAL354-73 recombinant phageThis studyPhage A491ARS45-pDAL491 recombinant phageThis studyPLEZ P2I-2ColE1 replicon containing the P <sub>lac/ara-1</sub> promoter)Lutz and Bujard (1997pACYC184cam-tet p15A repliconChang (1978)pDAL262pTZ18R containing a 271 bp papl DNA sequence (AB1))Nou et al. (1989)pDAL264pRS551 containing 1.6 kb paplB DNA sequence (AB1))Blyn et al. (1994)pDAL374pRS550 containing 1.76 kb paplB DNA sequence (papBAp-lac2)Braaten et al., (1994)pDAL354pDAL354 with GATC <sup>1028</sup> ste changed to GCTCBraaten et al. (1994)pDAL354-15pDAL354 with ATG start codon of papB changed to CTG (B15)This studypDAL354-73pDAL354 with a 503 bp papB/intergenic DNA deletion (AB59)This studypDAL354-73pDAL354 containing a 271 bp paplThis studypDAL354-74pDAL354 containing a 271 bp paplThis studypDAL354-75pDAL354 with a 503 bp papB/intergenic DNA sequenceThis studypDAL354-76pDAL354 with a for papl DNA sequenceThis studypDAL354-77pDAL354 containing a 271 bp paplThis studypDAL354-79pDAL354 containing a 271 bp paplThis study	Phage X354	ARS45-pDAL354 recombinant phage	Braaten <i>et al.</i> (1994)
Phage A354-59ARS45-pDAL354-51 recombinant phageThis studyPhage A354-59NRS45-pDAL354-59 recombinant phageThis studyPhage A354-73NRS45-pDAL491 recombinant phageThis studyPhage A491NRS45-pDAL491 recombinant phageThis studyPhage A491NRS45-pDAL491 recombinant phageThis studyPlasmidspUHE2 P2I-2ColE1 replicon containing the $P_{lac/ara-1}$ Lutz and Bujard (1997pCYC184cam-tet p15A repliconChang (1978)pDAL262pTZ18R containing a 271 bp pap/ DNANou et al. (1993)sequencepRS551 containing 1.6 kb pap/B DNABlyn et al. (1989)pDAL246pRS551 containing 1.76 kb pap/BBraaten et al. (1994)regulatory sequencepDAL354 with GATC <sup>1028</sup> site changedBraaten et al. (1994)pDAL354-15pDAL354 with ATG start codon of papBThis studypDAL354-59pDAL354 with a 503 bp pap//intergenicThis studypDAL354-73pDAL354 with a 503 bp pap//intergenicThis studypDAL354-73pDAL354 with a 13 pap / frameshiftThis studypDAL486pACYC184 containing a 271 bp pap/This studypDAL481pGEX-2T containing a 413 bp hns DNAThis studypDAL485pAS51 containing in 176 bp pap/BThis studypDAL485pACYC184 containing a 271 bp pap/This studypDAL481pGEX-2T containing a 413 bp hns DNAThis studypDAL485pAS51 containing introp pap/BThis studypDAL485pAS51 containing introp pap/BThis studypDAL485 <td>Phage X354-1</td> <td>ARS45-pDAL354-1 recombinant phage</td> <td>Braaten <i>et al.</i> (1994)</td>	Phage X354-1	ARS45-pDAL354-1 recombinant phage	Braaten <i>et al.</i> (1994)
Phage X364-59ARS45-pDAL354-73 recombinant phageThis studyPhage A491\RS45-pDAL491 recombinant phageThis studyPhage P1L4Virulent phage P1L. CaroPlasmidspUHE2 PzI-2ColE1 replicon containing the P <sub>lac/ara-1</sub> promoter)Lutz and Bujard (1997pACYC184 <i>cam-tet</i> p15A repliconChang (1978)pDAL262pTZ18R containing a 271 bp <i>papl</i> DNA sequenceNou <i>et al.</i> (1993)pDAL264pRS551 containing 1.6 kb <i>paplB</i> DNA sequence (AB1)Blyn <i>et al.</i> (1989)pDAL37pTZ19U containing a 1.76 kb <i>paplB</i> DNA sequence ( <i>papBAp-lac2</i> )Braaten <i>et al.</i> (1994)pDAL354with AGTC <sup>1028</sup> site changed to GCTCBraaten <i>et al.</i> (1994)pDAL354-11pDAL354 with AGTC <sup>1028</sup> site changed to GCTCBraaten <i>et al.</i> (1994)pDAL354-59pDAL354 with a 503 bp <i>papB</i> /intergenic DNA deletion (AB59)This studypDAL354-73pDAL354 containing a 271 bp <i>papl</i> This studypDAL354-73pDAL354 containing a 271 bp <i>papl</i> This studypDAL354-73pDAL354 containing a 271 bp <i>papl</i> This studypDAL481pGEX-2T containing a 176 bp <i>papl</i> This studypDAL485pRS551 inith multiple cloning site of EcoRI-Sph1-BarmHIThis studypDAL491pRS551 containing 1176 bp <i>paplB</i> This studypDAL485pRS551 inith multiple cloning site and GST DNA sequencesThis studypGEX-2Tplasmid containing Mns under Plac/ara-1 promoter control pRS551Amp-kan-lacZYA pMB1 repliconSimons <i>et al.</i> (1987)pPY1025 <t< td=""><td>Phage X354-15</td><td>ARS45-pDAL354-15 recombinant phage</td><td>This study</td></t<>	Phage X354-15	ARS45-pDAL354-15 recombinant phage	This study
Phage A91 Phage A91 ARS45-pDL2497 recombinant phage Phage P1L4This study L. CaroPlasmids pUHE2 P2I-2 promoter) pACYC184 pACYC184 pACYC184 cam-tet p15A replicon cam-tet p15A replicon pDAL262Lutz and Bujard (1997 Chang (1978) pACYC184 cam-tet p15A replicon pT218R containing a 271 bp papl DNA sequence PDAL262Lutz and Bujard (1997 Chang (1978) Nou et al. (1993) sequence (B11)pDAL262 pDAL354pTZ18R containing a 1.76 kb paplB DNA sequence (AB11)Blyn et al. (1989 sequence (AB11)pDAL354pRS550 containing 1.76 kb paplB DNA sequence (AB20)Braaten et al. (1994) regulatory sequence pDAL354 with ATG start codon of papB changed to CTG (B15)pDAL354-15 pDAL354 with a GO3 bp papB/intergenic DNA deletion (AB59)This study This study This studypDAL354-73 pDAL354 with a 503 bp papB/intergenic DNA deletion (AB59)This study This study This studypDAL468 pACYC184 containing a 271 bp paplThis study This study This studypDAL481 pDAL354-73pGEX-2T containing a 413 bp hns DNA sequenceThis study This studypDAL481 pDAL481pGEX-2T containing 1176 bp paplB DNA sequenceThis study This studypDAL569pUHE2 P21-2 containing hns under Plac/ara-1 promoter control prosts1 containing multiple cloning site and GST DNA sequencesThis study Pharmacia Biotech and PAR-In2CYA pMB1 replicon Simons et al. (1987) PY1025pPY1025pGB2 containing lacl <sup>4</sup> PLO2-Containing lacl <sup>4</sup> PLO2-Containing lacl <sup>4</sup>	Phage X354-59	ARS45-pDAL354-59 recombinant phage	This study
Phage P1L4Virulent phage P1Lts studyPlasmidspUHE2 PzI-2ColE1 replicon containing the P <sub>lac/ara-1</sub> Lutz and Bujard (1997pACYC184cam-tet p15A repliconChang (1978)pDAL262pTZ18R containing a 271 bp papl DNANou et al. (1993)sequencepDAL246pRS551 containing a 1.6 kb paplB DNABlyn et al. (1994)pDAL337pTZ19U containing a 1.76 kb paplB DNABraaten et al. (1994)regulatory sequence(pBAL354 - track of Containing 1.76 kb paplB DNABraaten et al. (1994)pDAL354pRS550 containing 1.76 kb paplB DNABraaten et al. (1994)regulatory sequence(pabAp-lacZ)BDAL354 with GATC <sup>1028</sup> site changedBraaten et al. (1994)pDAL354.1pDAL354 with ATG start codon of papBThis studyChanged to CTG (B15)pDAL354.59pDAL354 with a 50 3bp papB/intergenicThis studypDAL354.73pDAL354 containing a 271 bp paplThis studypDAL481pGEX-2T containing a 413 bp hns DNAThis studypDAL481pRS551 with multiple cloning site of EcoRI-SphI-BamHIThis studypDAL485pRS551 with multiple cloning site of EcoRI-SphI-BamHIThis studypDAL569pUHE2 P2-2 containing 1176 bp paplBThis studypDAL569pUHE2 P2-2 containing hrs underThis studypDAL569pLHE2 P2-2 containing hrs underThis studypCX-2Tplasmid containing hutiple cloning site and GST DNA sequencesPharmacia BiotechpRS551amp-kan-lacZYA pMB1 repliconSimons et al. (1987)pPY1025<	Phage X354-73	ARS45-pDAL354-73 recombinant phage	This study
Plage F1C4Vinden prage F1L. CaloPlasmidspUHE2 PzI-2ColE1 replicon containing the P <sub>lac/ara-1</sub> promoter)Lutz and Bujard (1997pACYC184cam-tet p15A repliconChang (1978)pDAL262pTZ18R containing a 271 bp pap/ DNA sequenceNou et al. (1993)pDAL262pRS551 containing a 1.76 kb pap/BBraaten et al. (1994) regulatory sequencepDAL337pTZ19U containing a 1.76 kb pap/B DNA sequence (papBAp-lac2)Braaten et al. (1994) regulatory sequencepDAL354.1pDAL354 with GATC <sup>1026</sup> site changed to CTG (B15)Braaten et al. (1994) to GCTCpDAL354.15pDAL354 with ATG start codon of papB changed to CTG (B15)This studypDAL354.73pDAL354 with a 503 bp pap/Intergenic DNA deletion (AB59)This studypDAL468pACYC184 containing a 271 bp pap/ DNA sequenceThis studypDAL481pGEX-2T containing a 413 bp hns DNA sequenceThis studypDAL481pGEX-2T containing a 1176 bp pap/B DNA sequenceThis studypDAL481pGEX-2T containing a 1176 bp pap/B DNA sequenceThis studypDAL485pRS551 with multiple cloning site of EcoRI-Sph1-BamHIThis studypDAL491pRS551 containing 1176 bp pap/B DNA sequenceThis studypGEX-2Tplasmid containing multiple cloning site and GST DNA sequencesPharmacia Biotech and GST DNA sequencespRS551amp-kan-lac2YA pMB1 replicon PF1025Simons et al. (1987) P. Youderian	Phage R491	Virulent phage P1	
Plasmids pUHE2 PzI-2ColE1 replicon containing the Plac/ara-1 promoter)Lutz and Bujard (1997pACYC184cam-tet p15A repliconChang (1978) Nou et al. (1993)pDAL262pTZ18R containing a 271 bp papl DNANou et al. (1993)pDAL264pRS551 containing 1.6 kb paplB DNA sequence (ΔB1))Blyn et al. (1989)pDAL337pTZ19U containing a 1.76 kb paplB regulatory sequenceBraaten et al. (1994)pDAL354pRS550 containing 1.76 kb paplB DNA sequence (papBAp-lacZ)Braaten et al. (1994)pDAL354.1pDAL354 with GATC <sup>1028</sup> site changed to GCTCBraaten et al. (1994)pDAL354.15pDAL354 with ATG start codon of papB changed to CTG (B15)This studypDAL354.73pDAL354 containing a papl frameshift DNA deletion (ΔB59)This studypDAL481pGEX-2T containing a 271 bp paplThis studypDAL485pRS551 with multiple cloning site of EcoRI-SphI-BarMHThis studypDAL481pGEX-2T containing a 176 bp paplB DNA sequenceThis studypDAL485pRS551 with multiple cloning site of EcoRI-SphI-BarMHThis studypDAL489pQEX-2T containing multiple cloning site of Bac/ara-1 promoter controlThis studypGEX-2Tplasmid containing multiple cloning site and GST DNA sequencesPharmacia Biotech and SST DNA sequencespRS551amp-kan-lacZYA pMB1 repliconSimons et al. (1987)pPY1025pGB2 containing lacl <sup>q</sup> P. Youderian	Flidge FliL4	virulent priage Fi	E. Calo
pACYC184 pDAL262cam-tet p15A replicon pT218R containing a 271 bp papl DNA sequenceChang (1978) Nou et al. (1993) sequence (ΔB1))pDAL246pRS551 containing 1.6 kb paplB DNA sequence (ΔB1))Blyn et al. (1989pDAL337pTZ19U containing a 1.76 kb paplB regulatory sequenceBraaten et al. (1994) regulatory sequencepDAL354pRS550 containing 1.76 kb paplB DNA sequence (papBAp-lacZ)Braaten et al. (1994) regulatory sequencepDAL354.11pDAL354 with GATC1028 site changed to GCTCBraaten et al. (1994) to GCTCpDAL354.55pDAL354 with ATG start codon of papB changed to CTG (B15)This study DNA deletion (ΔB59)pDAL354.73pDAL354 containing a papl frameshift mutationThis study This studypDAL468pACYC184 containing a 413 bp hns DNA sequenceThis study EcoRI-SphI-BamHIpDAL481pGEX-2T containing 1176 bp paplB DNA sequenceThis study This studypDAL485pRS551 with multiple cloning site of DNA sequenceThis studypDAL486pRS551 with multiple cloning site of DNA sequenceThis studypDAL485pRS551 with multiple cloning site of Acronare on the sequenceThis studypDAL569pUHE2 P2I-2 containing hns under and GST DNA sequencesThis studypRS550amp-kan-lacZYA pMB1 replicon A sequenceSimons et al. (1987) Simons et al. (1987) Simons et al. (1987)pRS551amp-kan-lacZYA pMB1 repliconSimons et al. (1987) Simons et al. (1987)	Plasmids pUHE2 PzI-2	CoIE1 replicon containing the P <sub>lac/ara-1</sub>	Lutz and Bujard (1997
pDAL262pTZ18R containing a 271 bp <i>papl</i> DNACharlg (1978)pDAL262pTZ18R containing a 271 bp <i>papl</i> DNANou <i>et al.</i> (1993)sequencepR5551 containing 1.6 kb <i>paplB</i> DNABlyn <i>et al.</i> (1993)pDAL337pTZ19U containing a 1.76 kb <i>paplB</i> Braaten <i>et al.</i> (1994)regulatory sequencepDAL354pR5550 containing 1.76 kb <i>paplB</i> DNApDAL354pR5550 containing 1.76 kb <i>paplB</i> DNABraaten <i>et al.</i> (1994)sequence ( <i>papBAp-lacZ</i> )pDAL354 with GATC <sup>1028</sup> site changedBraaten <i>et al.</i> (1994)pDAL354.1pDAL354 with ATG start codon of <i>papB</i> This studychanged to CTG (B15)pDAL354 with a 503 bp <i>papB</i> /intergenicThis studypDAL354.73pDAL354 containing a <i>papl</i> frameshiftThis studymutationpDAL468pACYC184 containing a 271 bp <i>papl</i> This studypDAL468pACYC184 containing a 413 bp <i>hns</i> DNAThis studypDAL481pGEX-2T containing a 176 bp <i>paplB</i> This studypDAL569pUHE2 PzI-2 containing 1176 bp <i>paplB</i> This studypDAL569pUHE2 PzI-2 containing 1176 bp <i>paplB</i> This studypGEX-2Tplasmid containing multiple cloning site of and GST DNA sequenceThis studypGEX-2Tplasmid containing multiple cloning site and GST DNA sequencePharmacia BiotechpR5551 <i>amp-kan-lacZYA</i> pMB1 repliconSimons <i>et al.</i> (1987)pR5551 <i>amp-kan-lacZYA</i> pMB1 repliconSimons <i>et al.</i> (1987)pPY1025pGB2 containing <i>lacl</i> <sup>q</sup> P. Youderian	= A C V C 1 0 4	promoter)	Chang (1079)
DAL262DT2 for Containing a 27 rbp papi DNANote et al. (1993)pDAL246pRS551 containing 1.6 kb papIB DNABlyn et al. (1989)pDAL337pTZ19U containing a 1.76 kb papIBBraaten et al. (1994)regulatory sequencepRS550 containing 1.76 kb papIB DNABraaten et al. (1994)pDAL354pRS550 containing 1.76 kb papIB DNABraaten et al. (1994)pDAL354pDAL354 with GATC <sup>1028</sup> site changedBraaten et al. (1994)to GCTCpDAL354 with GATC <sup>1028</sup> site changedBraaten et al. (1994)pDAL354-15pDAL354 with ATG start codon of papBThis studypDAL354-59pDAL354 with a 503 bp papB/intergenicThis studypDAL354-73pDAL354 containing a papI frameshiftThis studypDAL354-73pDAL354 containing a 271 bp papIThis studypDAL468pACYC184 containing a 271 bp papIThis studypDAL481pGEX-2T containing a 413 bp hns DNAThis studypDAL481pGEX-2T containing a 413 bp hns DNAThis studypDAL481pRS551 containing 1176 bp papIBThis studypDAL491pRS551 containing 1176 bp papIBThis studypDAL569pUHE2 PzI-2 containing hns underThis studypGEX-2Tplasmid containing multiple cloning site and GST DNA sequencesPharmacia BiotechpRS550amp-kan-lacZYA pMB1 repliconSimons et al. (1987)pPY1025pGB2 containing lacl <sup>q</sup> P. Youderian	pACTC184	pT718P containing a 271 hp pap/ DNA	$\frac{1978}{1902}$
pDAL246pRS551 containing 1.6 kb <i>papIB</i> DNABlyn <i>et al.</i> (1989pDAL337pTZ19U containing a 1.76 kb <i>papIB</i> Braaten <i>et al.</i> (1994)regulatory sequencepDAL354pRS550 containing 1.76 kb <i>papIB</i> DNABraaten <i>et al.</i> (1994)pDAL354pRS550 containing 1.76 kb <i>papIB</i> DNABraaten <i>et al.</i> (1994)sequence ( <i>papBAp-lacZ</i> )pDAL354 with GATC <sup>1028</sup> site changedBraaten <i>et al.</i> (1994)pDAL354-11pDAL354 with GATC <sup>1028</sup> site changedBraaten <i>et al.</i> (1994)to GCTCpDAL354 with ATG start codon of <i>papB</i> This studypDAL354-59pDAL354 with a 503 bp <i>papB/</i> intergenicThis studypDAL354-73pDAL354 containing a <i>papI</i> frameshiftThis studypDAL468pACYC184 containing a 271 bp <i>papI</i> This studypDAL481pGEX-2T containing a 413 bp <i>hns</i> DNAThis studypDAL485pRS551 with multiple cloning site ofThis studypDAL481pGEX-2T containing 1176 bp <i>papIB</i> This studypDAL569pUHE2 P2I-2 containing <i>hns</i> underThis studypGEX-2Tplasmid containing multiple cloning sitePharmacia Biotechand GST DNA sequencesPharmacia Biotechand GST DNA sequencespRS551 <i>amp-kan-lacZYA</i> pMB1 repliconSimons <i>et al.</i> (1987)pPY1025pGB2 containing <i>lacl<sup>q</sup></i> P. Youderian	PDALZOZ	prziłok containing a 27 rup papi DNA	Nou <i>et al.</i> (1993)
sequence ( $\Delta$ B1)) pDAL337sequence ( $\Delta$ B1)) regulatory sequenceBraaten <i>et al.</i> (1994) regulatory sequencepDAL354pRS550 containing 1.76 kb <i>papIB</i> DNA sequence ( <i>papBAp-lacZ</i> )Braaten <i>et al.</i> (1994) sequence ( <i>papBAp-lacZ</i> )pDAL354.1pDAL354 with GATC <sup>1028</sup> site changed to GCTCBraaten <i>et al.</i> (1994) to GCTCpDAL354.55pDAL354 with ATG start codon of <i>papB</i> changed to CTG (B15)This studypDAL354.59pDAL354 with a 503 bp <i>papB</i> /intergenic DNA deletion ( $\Delta$ B59)This studypDAL354.73pDAL354 containing a <i>papI</i> frameshift DNA sequenceThis studypDAL468pACYC184 containing a 271 bp <i>papI</i> DNA sequenceThis studypDAL481pGEX-2T containing a 413 bp <i>hns</i> DNA sequenceThis studypDAL485pRS551 with multiple cloning site of DNA sequenceThis studypDAL491pRS551 containing 1176 bp <i>papIB</i> DNA sequence ( <i>papIp-lacZ</i> )This studypDAL569pUHE2 PzI-2 containing <i>hns</i> under and GST DNA sequencesPharmacia BiotechpRS550 <i>amp-kan-lacZYA</i> pMB1 repliconSimons <i>et al.</i> (1987) Simons <i>et al.</i> (1987) PRS551 <i>amp-kan-lacZYA</i> pMB1 repliconSimons <i>et al.</i> (1987) P. Youderian	pDAL246	pRS551 containing 1.6 kb papIB DNA	Blyn <i>et al</i> . (1989
pDAL337p12190 containing a 1.76 kb papibbrazien et al. (1994)regulatory sequencepRS550 containing 1.76 kb papibBraaten et al., (1994)pDAL354pRS550 containing 1.76 kb papibBraaten et al., (1994)pDAL354.1pDAL354 with GATC <sup>1028</sup> site changed to GCTCBraaten et al. (1994)pDAL354.15pDAL354 with GATC <sup>1028</sup> site changed to GCTCBraaten et al. (1994)pDAL354.75pDAL354 with ATG start codon of papB changed to CTG (B15)This studypDAL354.73pDAL354 with a 503 bp papB/intergenic DNA deletion (ΔB59)This studypDAL468pACYC184 containing a papi frameshift DNA sequenceThis studypDAL468pGEX-2T containing a 113 bp hns DNA sequenceThis studypDAL485pRS551 with multiple cloning site of DNA sequence (papib-lacZ)This studypDAL491pRS551 containing 1176 bp papiB DNA sequence (papib-lacZ)This studypDAL569pUHE2 P2I-2 containing hns under Plac/ara-1 promoter controlThis studypGEX-2Tplasmid containing multiple cloning site and GST DNA sequencesPharmacia BiotechpRS551amp-kan-lacZYA pMB1 repliconSimons et al. (1987)pRS551amp-kan-lacZYA pMB1 repliconSimons et al. (1987)pPY1025pGB2 containing lacl <sup>q</sup> P. Youderian	DAI 227	sequence ( $\Delta$ B1))	Braaton at al. (1004)
pDAL354pRS550 containing 1.76 kb papIB DNA sequence (papBAp-lacZ)Braaten et al., (1994)pDAL354-1pDAL354 with GATC <sup>1028</sup> site changed to GCTCBraaten et al. (1994)pDAL354-15pDAL354 with GATC <sup>1028</sup> site changed to GCTCBraaten et al. (1994)pDAL354-59pDAL354 with ATG start codon of papB changed to CTG (B15)This studypDAL354-73pDAL354 containing a papI frameshift mutationThis studypDAL468pACYC184 containing a 271 bp papI DNA sequenceThis studypDAL481pGEX-2T containing a 413 bp hns DNA sequenceThis studypDAL491pRS551 with multiple cloning site of EcoRI-SphI-BamHIThis studypDAL569pUHE2 PzI-2 containing multiple cloning site A sequenceThis studypDAL569pUHE2 PzI-2 containing multiple cloning site A sequenceThis studypRS551amp-kan-lacZYA pMB1 repliconSimons et al. (1987) Simons et al. (1987)pRS551amp-kan-lacZYA pMB1 repliconSimons et al. (1987) P. Youderian	PDAESSI	regulatory sequence	
pDAL354-1pDAL354 with GATC 1028 site changed to GCTCBraaten <i>et al.</i> (1994) to GCTCpDAL354-15pDAL354 with AG start codon of <i>papB</i> changed to CTG (B15)This studypDAL354-59pDAL354 with a 503 bp <i>papB</i> /intergenic DNA deletion (\aB59)This studypDAL354-73pDAL354 containing a <i>papI</i> frameshift mutationThis studypDAL468pACYC184 containing a 271 bp <i>papI</i> DNA sequenceThis studypDAL481pGEX-2T containing a 413 bp <i>hns</i> DNA SequenceThis studypDAL485pRS551 with multiple cloning site of DNA sequence ( <i>papI-lacZ</i> )This studypDAL569pUHE2 PzI-2 containing <i>hns</i> under And GST DNA sequencesThis studypDAL569pUHE2 PzI-2 containing multiple cloning site DNA sequence studyThis studypS550 <i>amp-kan-lacZYA</i> pMB1 repliconSimons <i>et al.</i> (1987) Simons <i>et al.</i> (1987) pPY1025Simons <i>et al.</i> (1987) P. Youderian	pDAL354	pRS550 containing 1.76 kb <i>papIB</i> DNA	Braaten et al., (1994)
pDAL354-15pDAL354 with ATG start codon of $papB$ changed to CTG (B15)This studypDAL354-59pDAL354 with a 503 bp $papB/$ intergenic DNA deletion ( $\Delta B59$ )This studypDAL354-73pDAL354 containing a $papl$ frameshift mutationThis studypDAL468pACYC184 containing a 271 bp $papl$ DNA sequenceThis studypDAL481pGEX-2T containing a 413 bp $hns$ DNA sequenceThis studypDAL485pRS551 with multiple cloning site of EcoRI- $SphI-BamHI$ This studypDAL569pUHE2 PzI-2 containing $hns$ under PAL481This studypDAL491pRS551 containing multiple cloning site and GST DNA sequencesThis studypDAL569pUHE2 PzI-2 containing $hns$ under and GST DNA sequencesThis studypRS550 $amp-kan-lacZYA$ pMB1 repliconSimons et al. (1987)pRS551 $amp-kan-lacZYA$ pMB1 repliconSimons et al. (1987)pPY1025pGB2 containing $lacl^q$ P. Youderian	nDAI 354-1	nDAL354 with GATC <sup>1028</sup> site changed	Braaten <i>et al.</i> (1994)
pDAL354-15pDAL354 with ATG start codon of papBThis study changed to CTG (B15)pDAL354-59pDAL354 with a 503 bp papB/intergenic DNA deletion (ΔB59)This studypDAL354-73pDAL354 containing a papI frameshift mutationThis studypDAL468pACYC184 containing a 271 bp papI DNA sequenceThis studypDAL481pGEX-2T containing a 413 bp hns DNA sequenceThis studypDAL485pRS551 with multiple cloning site of EcoRI-SphI-BamHIThis studypDAL569pUHE2 P2I-2 containing hns under Plac/ara-1 promoter controlThis studypGEX-2Tplasmid containing multiple cloning site and GST DNA sequencesPharmacia BiotechpRS550amp-kan-lacZYA pMB1 repliconSimons et al. (1987) Simons et al. (1987) PrY1025Simons et al. (1987) P. Youderian	PB/(20011	to GCTC	Bradion of an (1001)
pDAL354-59pDAL354 with a 503 bp papB/intergenicThis studypDAL354-73pDAL354 containing a papI frameshiftThis studypDAL354pDAL354 containing a papI frameshiftThis studypDAL468pACYC184 containing a 271 bp papIThis studypDAL468pACYC184 containing a 413 bp hns DNAThis studypDAL481pGEX-2T containing a 413 bp hns DNAThis studypDAL485pRS551 with multiple cloning site of EcoRI-SphI-BamHIThis studypDAL491pRS551 containing 1176 bp papIBThis studypDAL569pUHE2 PzI-2 containing hns under Plac/ara-1 promoter controlThis studypGEX-2Tplasmid containing multiple cloning site and GST DNA sequencesPharmacia BiotechpRS550amp-kan-lacZYA pMB1 repliconSimons et al. (1987)pRS551amp-kan-lacZYA pMB1 repliconSimons et al. (1987)pPY1025pGB2 containing lacl <sup>q</sup> P. Youderian	pDAL354-15	pDAL354 with ATG start codon of <i>papB</i>	This study
DNA deletion (ΔB59)pDAL354-73pDAL354 containing a papl frameshiftThis studymutationpDAL468pACYC184 containing a 271 bp paplThis studypDAL468pACYC184 containing a 413 bp hns DNAThis studypDAL481pGEX-2T containing a 413 bp hns DNAThis studysequencepDAL485pR5551 with multiple cloning site ofThis studypDAL491pR5551 containing 1176 bp paplBThis studypDAL569pUHE2 P2I-2 containing hns underThis studypGEX-2Tplasmid containing multiple cloning sitePharmacia Biotechand GST DNA sequencesSimons et al. (1987)pRS551amp-kan-lacZYA pMB1 repliconSimons et al. (1987)pPY1025pGB2 containing lacl <sup>q</sup> P. Youderian	pDAL354-59	pDAL354 with a 503 bp <i>papB</i> /intergenic	This study
pDAL304+73pDAL304 containing a paperimensionThis studymutationmutationThis studypDAL468pACYC184 containing a 271 bp paplThis studypDAL481pGEX-2T containing a 413 bp hns DNAThis studysequencesequenceThis studypDAL485pR5551 with multiple cloning site ofThis studypDAL491pR5551 containing 1176 bp paplBThis studypDAL569pUHE2 P2I-2 containing hns underThis studypGEX-2Tplasmid containing multiple cloning sitePharmacia Biotechand GST DNA sequencesSimons et al. (1987)pRS551amp-kan-lacZYA pMB1 repliconSimons et al. (1987)pPY1025pGB2 containing lacl <sup>q</sup> P. Youderian	nDAI 254 72	DNA deletion ( $\Delta B59$ )	This study
pDAL468pACYC184 containing a 271 bp papl DNA sequenceThis studypDAL481pGEX-2T containing a 413 bp hns DNAThis study sequencepDAL481pGEX-2T containing a 413 bp hns DNAThis study sequencepDAL485pR5551 with multiple cloning site of EcoRI-SphI-BamHIThis studypDAL491pR5551 containing 1176 bp paplB DNA sequence (paplp-lacZ)This study Plac/ara-1 promoter controlpGEX-2Tplasmid containing multiple cloning site and GST DNA sequencesPharmacia Biotech and GST DNA sequencespRS550amp-kan-lacZYA pMB1 repliconSimons et al. (1987) Simons et al. (1987) PrY1025pPY1025pGB2 containing lacl <sup>q</sup> P. Youderian	pDAL334-73	mutation	This study
pDAL481   pGEX-2T containing a 413 bp hns DNA   This study     pDAL485   pRS551 with multiple cloning site of   This study     pDAL485   pRS551 with multiple cloning site of   This study     pDAL491   pRS551 containing 1176 bp pap/B   This study     pDAL569   pUHE2 PzI-2 containing hns under   This study     pGEX-2T   plac/ara-1 promoter control   Plac/ara-1 promoter control     pRS550   amp-kan-lacZYA pMB1 replicon   Simons et al. (1987)     pRS551   amp-kan-lacZYA pMB1 replicon   Simons et al. (1987)     pPY1025   pGB2 containing lacl <sup>q</sup> P. Youderian	pDAL468	pACYC184 containing a 271 bp <i>papl</i>	This study
sequence   sequence     pDAL485   pRS551 with multiple cloning site of   This study     pDAL491   pRS551 containing 1176 bp papIB   This study     pDAL569   pUHE2 PzI-2 containing hns under   This study     pGEX-2T   plasmid containing multiple cloning site   Pharmacia Biotech     and GST DNA sequences   amp-kan-lacZYA pMB1 replicon   Simons et al. (1987)     pRS551   amp-kan-lacZYA pMB1 replicon   Simons et al. (1987)     pPY1025   pGB2 containing lacl <sup>q</sup> P. Youderian	pDAL481	pGEX-2T containing a 413 bp hns DNA	This study
pDAL435   pRS351 with multiple cloning site of the study   This study     pDAL491   pRS551 containing 1176 bp papIB   This study     pDAL569   pUHE2 PzI-2 containing hns under   This study     pGEX-2T   plac/ara-1 promoter control   Pharmacia Biotech     pRS550   amp-kan-lacZYA pMB1 replicon   Simons et al. (1987)     pRS551   amp-kan-lacZYA pMB1 replicon   Simons et al. (1987)     pPY1025   pGB2 containing lacl <sup>q</sup> P. Youderian	DAL 495	sequence	This study
pDAL491 pRS551 containing 1176 bp pap/B This study   pDAL569 pUHE2 PzI-2 containing hns under This study   pDAL569 pUHE2 rescurption This study   pGEX-2T plasmid containing multiple cloning site Pharmacia Biotech   and GST DNA sequences Simons et al. (1987)   pRS550 amp-kan-lacZYA pMB1 replicon Simons et al. (1987)   pRS551 amp-kan-lacZYA pMB1 replicon Simons et al. (1987)   pPY1025 pGB2 containing lacl <sup>q</sup> P. Youderian	pDAL405	EcoRI-SphI-BamHI	This study
DNA sequence (paplp-lacZ)     pDAL569   pUHE2 PzI-2 containing hns under     Plac/ara-1 promoter control   Plasmid containing multiple cloning site     pGEX-2T   plasmid containing multiple cloning site     pRS550   amp-kan-lacZYA pMB1 replicon     pRS551   amp-kan-lacZYA pMB1 replicon     Simons et al. (1987)     pPY1025   pGB2 containing lacl <sup>q</sup>	pDAL491	pRS551 containing 1176bp papIB	This study
pDAL569 pUHE2 PzI-2 containing hns under This study   Plac/ara-1 promoter control Plasmid containing multiple cloning site Pharmacia Biotech   pGEX-2T plasmid containing multiple cloning site Pharmacia Biotech   pRS550 amp-kan-lacZYA pMB1 replicon Simons et al. (1987)   pRS551 amp-kan-lacZYA pMB1 replicon Simons et al. (1987)   pPY1025 pGB2 containing lacl <sup>q</sup> P. Youderian	•	DNA sequence (papIp-lacZ)	
Plac/ara-1 promoter control   Plac/ara-1 promoter control     pGEX-2T   plasmid containing multiple cloning site and GST DNA sequences   Pharmacia Biotech     pRS550   amp-kan-lacZYA pMB1 replicon   Simons et al. (1987)     pRS551   amp-kan-lacZYA pMB1 replicon   Simons et al. (1987)     pPY1025   pGB2 containing lacl <sup>q</sup> P. Youderian	pDAL569	pUHE2 PzI-2 containing hns under	This study
pGEX-2T plasmid containing multiple cloning site and GST DNA sequences Pharmacia Biotech   pRS550 amp-kan-lacZYA pMB1 replicon Simons et al. (1987)   pRS551 amp-kan-lacZYA pMB1 replicon Simons et al. (1987)   pPY1025 pGB2 containing lacl <sup>q</sup> P. Youderian		Plac/ara-1 promoter control	
and GST DNA sequences   pRS550 amp-kan-lacZYA pMB1 replicon Simons et al. (1987)   pRS551 amp-kan-lacZYA pMB1 replicon Simons et al. (1987)   pPY1025 pGB2 containing lacl <sup>q</sup> P. Youderian	pGEX-2T	plasmid containing multiple cloning site	Pharmacia Biotech
pRS550amp-kan-lacZYA pMB1 repliconSimons et al. (1987)pRS551amp-kan-lacZYA pMB1 repliconSimons et al. (1987)pPY1025pGB2 containing lacl <sup>q</sup> P. Youderian		and GST DNA sequences	
pRS551amp-kan-lacZYA pMB1 repliconSimons et al. (1987)pPY1025pGB2 containing lacl <sup>q</sup> P. Youderian	pRS550	amp-kan-lacZYA pMB1 replicon	Simons et al. (1987)
pPY1025 pGB2 containing <i>lacl</i> <sup>4</sup> P. Youderian	pRS551	amp-kan-lacZYA pMB1 replicon	Simons <i>et al</i> . (1987)
	pPY1025	pGB2 containing lacl <sup>9</sup>	P. Youderian

© 1998 Blackwell Science Ltd, Molecular Microbiology, 28, 1121-1137

Strain	<i>pap</i> operon fusion	Mutation	<i>papl</i> plasmid	37°C Switch frequency <sup>a</sup> (events/cell/generation)	
				ON to OFF	OFF to ON
DL2838	paplp-lac	wt	_	1.79×10 <sup>-2</sup>	$4.85 \times 10^{-4}$
DL1504 <sup>b</sup>	papBAp-lac	wt	_	2.35×10 <sup>-2</sup>	$5.54 \times 10^{-4}$
DL3052	papBAp–lac	papl frameshift	_	NA <sup>c</sup>	NA
DL3056	papBAp–lac	papI frameshift	pDAL468	$1.28 \times 10^{-2}$	$3.87 \times 10^{-3}$
DL2208	papBAp–lac	papB CTG start codon	_	NA	NA
DL2773	papBAp–lac	papB CTG start codon	pDAL468	1.56×10 <sup>-2</sup>	$3.79 \times 10^{-3}$
DL1947	papBAp–lac	hns651	-	$3.65 \times 10^{-2}$	$1.66 \times 10^{-4}$

Table 2. Pap phase switch frequencies for papIp and papBAp operon fusions.

a. Pap switch frequencies were measured as described in Experimental procedures.

b. Nou et al. (1995).

c. NA, not applicable.

DL1504, which was transcriptionally inactive at 23°C (21 units, Table 3), plating of isolate DL2223 at 23°C showed that phase ON colonies were present (data not shown) and  $\beta$ -galactosidase levels were higher than those of DL1504 (between 500 and 1000 Miller units depending on IPTG concentration, Fig. 2A). The ratio of *papBA* expression at 37°C compared with 23°C for strain DL2223 was decreased as PapI expression was induced via the addition of IPTG. At 10  $\mu$ M IPTG, the 37°C/23°C ratio was less than one, indicating that the thermoregulatory response was blocked by PapI addition.

## PapI and PapB are not required for Pap thermoregulation

The results above and previous data (Göransson *et al.*, 1989a) indicated that *papl* transcription was thermoregulated and that overexpression of Papl disrupted thermoregulation of the *papBAp* promoter. To explore the relationship between Papl levels and thermoregulation further, we constructed a low-copy plasmid (pDAL468) that constitutively expressed Papl under the control of a vector promoter. Immunoblot analysis showed that the amount of Papl in *E. coli* DL1504 containing pDAL468 (DL2771)

was significantly higher than that of Papl expressed from E. coli DL1504 lacking this plasmid, and the Papl level of cells containing pDAL468 grown at 23°C was higher than that of cells grown at 37°C (Fig. 2B, inset). This higher level of PapI expressed by plasmid pDAL468 resulted in a sevenfold increase in the OFF to ON switch frequency and a twofold increase in papBA transcription (compare E. coli DL3056 with DL1504, Table 2 and Fig. 2B). The papl frameshift mutation in E. coli DL3052 was complemented at 37°C when transformed with plasmid pDAL468, constructing isolate DL3056 (Fig. 2B). However, at 23°C, transcription from the papBAp promoter was still thermoregulated as evidenced by a sixfold reduction in papBA transcription at 23°C compared with 37°C (DL3056, Fig. 2B). Similar 23°C results (eightfold reduction) were obtained after the introduction of pDAL468 into E. coli isolate DL1504, the wild-type *papBAp-lacZ* fusion, constructing isolate DL2771 (Fig. 2B). These results showed that the Pap thermoregulatory response did not correlate with the amount of Papl present, as papBA transcription was reduced at 23°C compared with 37°C under conditions in which the amount of Papl was higher at 23°C than it was at 37°C.

In a second approach to determine the relationship between PapI and *papBA* thermoregulation, we analysed

	Genotype	CAA added (0.2%)	$\beta$ -Galactosidase activity <sup>a</sup>		
Strain			37°C	23°C	37°C/23°C β-galactosidase ratio
DL1504	Wild type	_	$1082\pm241$	21±6	52
DL1947	hns651	_	$184 \pm 7$	$178 \pm 15$	1
DL1504	Wild type	+	$76 \pm 33$	$5\pm1$	15
DL1947	hns651	+	$130 \pm 9$	$174 \pm 21$	1
DL1505	GCTC-I	+	$1989\pm293$	$47 \pm 4$	42
DL1965	GCTC-I hns651	+	$1290\pm365$	$768 \pm 221$	2
DL1910	$\Delta lrp$	+	$4\pm 2$	$3\pm 2$	1
DL1948	$\Delta lrp$ hns 651	+	$645\pm49$	$694 \pm 116$	1

Table 3. H-NS is required for thermoregulation of *papBA* transcription.

**a.** β-galactosidase activity is expressed as Miller units (Miller, 1972) and was measured as described in *Experimental procedures*. Analyses were at either 37°C or at 23°C in M9 glycerol medium with 0.2% casamino acids added where indicated. Error is expressed as ± 1 standard deviation from the mean.

© 1998 Blackwell Science Ltd, Molecular Microbiology, 28, 1121-1137



**Fig. 2.** Quantitation of the effects of Papl on *pap* thermoregulation.

A. The effects of increasing levels of PapI on papBA transcription at 23°C and 37°C. For this study, E. coli isolate DL2223 containing a wild-type papBAp-lacZ fusion, high plasmid pDAL262 (*lacZp-papI*) and plasmid pPY1025 (lacl<sup>q</sup>) was used. The levels of IPTG shown were added to cultures to induce expression of PapI, and the expression of β-galactosidase from the papBAP-lacZ fusion was measured (Miller units) (Miller, 1972). B. The analysis of papBAp expression at 23°C and 37°C from both wild-type and pap mutant constructs (see Experimental procedures). The error bars represent one standard deviation from the mean. The inset shows Papl levels from E. coli isolates containing low-copy plasmid pDAL468, detected by immunoblotting (Experimental procedures). When papl was in single copy, PapI protein was undetectable (E. coli DL1504).

*E. coli* DL1505, which displayed a PapI-independent locked ON phenotype at 37°C as a result of a mutation in the GATC-I site (GCTC-I) that precludes methylation by Dam (Braaten *et al.*, 1994). Transcription from the *papBAp* promoter was still thermoregulated in *E. coli* DL1505 to a level similar to wild-type isolate DL1504 (37-fold decrease at 23°C compared with 37°C, Fig. 2B). Deletion of the *papI* gene reduced *papBA* transcription twofold at 37°C but did not significantly affect the LacZ expression level measured at 23°C. Thus, PapI was not required for the repression of *papBA* transcription at low temperature. Taken together, these results showed that, although very high levels of PapI resulted in the expression of *papBA* transcripts at 23°C, the intracellular level of PapI did not correlate with the level of thermoregulation, and PapI was not required for thermoregulation of *papBAp* transcription.

To examine the role of the PapB protein in the thermoregulation of *papBA* transcription, *papBAp–lacZ* fusions containing mutations in the *papB* gene and DNA regions downstream of *papB* were analysed for transcription at 37°C and 23°C. Strain DL2208 contains a *papBAp–lacZ* fusion in which the ATG start codon of the *papB* gene was altered to CTG (designated as the B15 mutation). Transcription of *papBA* in DL2208 was blocked at both 23°C and 37°C (Fig. 3) owing to the loss of translation of PapB, which was necessary for the activation of transcription of *papI* (Båga *et al.*, 1985; Forsman *et al.*, 1989) PapI, in turn, was required for *papBA* transcription. To restore



**Fig. 3.** Quantitation of the effects of *papB* on *pap* thermoregulation. The effects of mutations within the *papB* DNA region on transcription from *papBAp–lacZ* operon fusions were measured by quantitation of  $\beta$ -galactosidase activity (*Experimental procedures*). The *pap* mutations shown at the bottom are depicted in Fig. 1. The error bars represent one standard deviation from the mean.

*papBA* transcription in mutant isolate DL2208, the lowcopy plasmid pDAL468 expressing PapI was introduced to construct isolate DL2773 (Table 1). This resulted in the restoration of *papBA* transcription and phase switching at 37°C (Table 2), supporting the conclusion that PapB activates *papBA* transcription indirectly by activating *papI* transcription and PapI expression. At 23°C, transcription of the *papBA* genes was reduced, as demonstrated by a uniform Lac<sup>-</sup> colony phenotype. Measurement of β-galactosidase activities showed that the transcription of *papBA* was reduced sixfold at 23°C compared with 37°C in DL2773 (Fig. 3). These results showed that thermoregulation occurred in the absence of the PapB protein and, thus, PapB was not required for the thermoregulatory response.

## DNA sequences within papB are required for Pap thermoregulation

The results above strongly indicated that PapI and PapB were not required for *pap* thermoregulation. To determine if DNA sequences within the *pap* regulatory region played a role in thermoregulation, we constructed *pap* deletions downstream of the *papBAp* promoter (Fig. 1). Deletion of the entire *papB* coding sequence and the downstream region to *pap* bp 1720 (Fig. 3,  $\Delta$ B59) greatly reduced *pap* transcription at both 23°C and 37°C as expected, as PapB activates *papBA* transcription indirectly as discussed above. Complementation with low-copy plasmid pDAL468 (PapI<sup>+</sup>) resulted in a level of *papBA* transcription at 37°C near to that of wild-type *pap*, but no decrease in transcription was observed at 23°C (Fig. 3, DL2774). In contrast, deletion of *pap* bp 1603–1760 ( $\Delta$ B1) did not affect the thermoregulatory response significantly, indicating that

#### Control of Pap thermoregulation by H-NS 1127

this downstream intergenic sequence was not necessary for thermoregulation (Fig. 3, DL379). Together, these results showed that DNA sequences within the *papB* region were necessary for *papBA* thermoregulation.

#### H-NS is required for Pap thermoregulation

Previous work demonstrated that a mutation in hns designated drdX disrupted temperature-dependent repression of pap gene expression from multicopy plasmids (Göransson et al., 1990). We determined the effect of H-NS on papBA transcription from the single-copy chromosomal pap operon by transduction of the hns651 insertion mutation (Falconi et al., 1991) into E. coli isolate DL1504 to construct DL1947 (Table 1). Thermoregulation of pap transcription in the hns<sup>+</sup> control isolate DL1504 (a 37°C/23°C ratio of 52) was lost in the absence of H-NS (37°C/23°C ratio of 1; DL1947, Table 3). Similar results were obtained in medium containing casamino acids, which increased the growth rate of cells lacking H-NS by about twofold. Although casamino acids reduced the LacZ level of DL1504, thermoregulation of pap transcription still occurred (Table 3). These results indicated that H-NS was required for thermoregulation of *papBA* transcription.

The  $\beta$ -galactosidase expression measured for DL1947 in M9 glycerol medium at 37°C was significantly lower than that observed for the wild-type strain DL1504 grown at 37°C (Table 3). This decrease in  $\beta$ -galactosidase expression at 37°C was caused by a low percentage of phase ON bacteria in the DL1947 cultures (4–8%). Based on this observation, phase variation rates were measured for the *hns651* mutant strain DL1947 at 37°C. The phase ON to phase OFF switch frequency was 1.5-fold higher than the wild-type strain DL1504, and the phase OFF to phase ON switch frequency was threefold lower in the *hns651* mutant (Table 2). These data indicated that H-NS was not only required for thermoregulation of *papBA* transcription at 23°C, but also influenced the rate at which bacteria switched between phase states at 37°C.

Because only a small fraction of *E. coli* lacking H-NS were in the *pap* phase ON transcription state, we analysed *E. coli* DL1505 containing the GCTC-I mutation, which was phase-locked ON at 37°C. These mutant cells showed a 42-fold thermoregulatory response at 23°C similar to wild-type *E. coli* (Table 3). Introduction of the *hns651* mutation (DL1965) almost completely inhibited the thermoregulatory response, supporting the conclusion that H-NS was required for the thermoregulation of *papBA* transcription.

#### H-NS is a temperature-dependent DNA methylation blocking factor

In vivo methylation protection analysis. The data presented above showing that H-NS as well as DNA



Fig. 4. Analysis of the temperature dependence of pap DNA methylation patterns from wild-type and mutant E. coli strains. The E. coli strains analysed are shown at the top: DL1504 (wt), DL1910 (Δ*lrp*), DL1947 (hns651) and DL1948 ( $\Delta lrp$ , hns651) (Table 1). The restriction enzyme Mbol, which digests only fully non-methylated GATC sites, was added where indicated. Restriction enzyme EcoR1, which cuts at two sites flanking the entire pap regulatory region, was added to all samples. DNAs for analysis were isolated from bacteria grown at 23°C or 37°C, as indicated. The figure at the top is a Southern blot of the restriction digests using the 1.76 kb pap DNA probe shown. Each band in the Southern blot shown has been given a letter designation that corresponds to the diagram below. Bands 'B' and 'C represent a non-methylated GATC-II site, whereas bands 'D' and 'E' represent a nonmethylated GATC-I site.

sequences within or near *papB* were required for Pap thermoregulation suggested the possibility that H-NS (or an H-NS-regulated factor) might bind in a temperaturedependent manner to *pap* regulatory DNA. This hypothesis was tested by monitoring the methylation patterns of the *pap* GATC-I and GATC-II sites using Southern blot analysis. As Lrp protects these *pap* GATC sites from Dam methylation (see *Introduction*), we reasoned that binding of H-NS might have a similar effect. DNAs isolated from cells grown at 23°C and 37°C were digested with the restriction endonucleases *Eco*RI, which cuts at the borders of the *pap* regulatory DNA region, and *Mbo*I, which cuts only non-methylated GATC sites (Braaten *et al.*, 1994).

The wild-type strain DL1504 grown at either 37°C or 23°C predominantly displayed a phase OFF DNA methylation pattern based on the presence of DNA fragments 'B' and 'C', which result from *Mbol* digestion at non-methylated GATC-II sites (Fig. 4). This high fraction of DNA with a phase OFF methylation pattern correlated well with the

low amount of transcription observed in casamino acids at both temperatures tested (DL1504, Table 3). To determine the effect of H-NS on methylation protection of the pap GATC sites, an Lrp<sup>-</sup> E. coli isolate (DL1910) was analysed specifically to distinguish H-NS-mediated methylation protection. At 37°C, very little protection of either pap GATC site was observed in the absence of Lrp (Fig. 4, lane 8), consistent with previous data showing that, at 37°C, Lrp is the major methylation blocking factor for pap regulatory DNA (Braaten et al., 1991). Transcription of papBA was shut off in isolate DL1910, as Lrp is essential for pap transcription (Table 3). In contrast, at 23°C, methylation protection of both the GATC-I and the GATC-II sites was observed (Fig. 4, lane 6) as evidenced by the presence of DNA fragment pairs 'D/E' and 'B/C' respectively. These results indicated that another protein besides Lrp protected the GATC sites from methylation by Dam at 23°C but not at 37°C.

To determine if the temperature-dependent protection of



Fig. 5. Quantitation of H-NS levels as a function of temperature. Immunoblot analysis using antiserum raised against H-NS was carried out as described in *Experimental procedures*. Equal amounts ( $20 \mu g$ ) of total cellular protein were loaded in each lane. The 'C' lane contained cell extract from *E. coli* DL1947 *hns651* grown at 37°C (Table 1).

the pap GATC sites observed required H-NS, we measured the effect of the hns651 mutation on methylation protection of the pap GATC sites in Irp<sup>+</sup> and Irp<sup>-</sup> backgrounds. E. coli (*Irp*<sup>+</sup>) containing the *hns651* mutation (DL1947) showed a predominantly phase OFF DNA methylation pattern at both 23°C and 37°C (Fig. 4, lanes 10 and 12) owing to a low level of phase ON cells in medium containing casamino acids, as discussed above. Introduction of hns651 into Lrp<sup>-</sup> isolate DL1910 (DL1948) showed that neither pap GATC site was protected from DNA methylation at 23°C or 37°C (Fig. 4, lanes 14 and 16). These results indicated that H-NS or an H-NS-regulated protein was required for temperature-dependent protection of the pap GATC sites from Dam methylation. The basal papBA transcription observed in the absence of Lrp and H-NS in DL1948, which is independent of the upstream Lrp binding sites (van der Woude et al., 1995), was not thermoregulated (Table 3). This result was consistent with the data above and previous results (Göransson et al., 1990) indicating that H-NS was required for pap thermoregulation.

The H-NS-dependent methylation protection of the *pap* GATC-I and GATC-II sites observed at 23°C could be the result of a temperature-dependent increase in H-NS level. However, immunoblot analysis of *E. coli* DL1504 demonstrated that there was only a 1.5-fold increase in H-NS at 23°C compared with 37°C (Fig. 5A). Moreover, there was no increase in the H-NS level at 23°C compared

#### Control of Pap thermoregulation by H-NS 1129

with 30°C, and yet Pap phase variation occurred at 30°C with switch frequencies similar to those measured at 37°C (Blyn *et al.*, 1989). Similar results were obtained with the Lrp<sup>-</sup> isolate DL1910 used to analyse the role of H-NS in *pap* GATC site methylation protection (Fig. 5B). These results indicated that the H-NS-dependent methylation protection of *pap* GATC sites was not the result of an increase in the H-NS level at 23°C.

In vitro DNA binding and methylation protection analyses. The results shown in Fig. 4 indicated that H-NS or a factor regulated by H-NS blocked methylation of the GATC-I and GATC-II sites in the pap regulatory region at 23°C. By analogy with Lrp, which binds to and is required to block methylation of these pap GATC sites (Braaten et al., 1994; Nou et al., 1995), we determined if H-NS bound specifically to the pap regulatory region containing the GATC-I and GATC-II sites. This was carried out at 23°C with a competitive electrophoretic mobility shift assay (EMSA), which has been used previously to show that H-NS bound specifically to bent DNA upstream of the proU promoter (Lucht et al., 1994). Plasmid pDAL337 containing a 1.76 kb pap regulatory DNA fragment was digested with restriction endonucleases as shown in Fig. 6A to yield different-sized vector and pap-specific DNA fragments. These DNA fragments were incubated with purified H-NS and analysed by EMSA. As shown in Fig. 6B, H-NS had the highest affinity for the 363 bp pap DNA fragment containing the GATC-I and GATC-II sites (see arrow), with complete shift occurring at 0.7 µM H-NS. This affinity of H-NS for the upstream regulatory region of the papBAp promoter was similar to that measured for the proU promoter (Lucht et al., 1994). In contrast, complete shift of the papl (854 bp) and papB (543 bp) containing DNA fragments as well as vector DNAs (146, 1268 and 1449 bp) occurred at higher H-NS concentrations (Fig. 6B). These results indicated that H-NS specifically bound to the pap regulatory region containing GATC-I and GATC-II.

To determine if methylation of the pap regulatory DNA by Dam was blocked by H-NS, an in vitro methylation protection assay was carried out. A 327 bp non-methylated pap regulatory DNA fragment (Fig. 6A) was radiolabelled at the GATC-I proximal end and incubated with H-NS, followed by the addition of Dam. To determine the methylation state of the pap GATC sites, DNAs were phenol extracted to remove H-NS and incubated with Mbol. which digests only at non-methylated GATC sites. As shown in Fig. 7, digestion of the non-methylated 327 bp pap DNA (designated 'uncut') with Mbol yielded a 125 bp radiolabelled fragment, representing digestion at GATC-I (Fig. 7A, lanes 1 and 2). Treatment of the 327 bp pap DNA with Dam inhibited Mbol digestion (Fig. 7A, lane 3), indicating that, under these conditions, the pap GATC sites were 100% methylated. To determine if H-NS could



#### Fig. 6. Competitive electrophoretic mobility shift assay.

A. A restriction map of plasmid pDAL337 is shown at the top. The basepair locations of each restriction site are shown relative to the single *Eco*RI site, and the sizes of each DNA restriction fragment are shown. The bottom portion of the figure shows an expanded view of the 363 bp *pap* regulatory region including locations of the divergent *papIp* and *papBAp* promoters, the six Lrp binding sites that include the GATC-I and GATC-II sites (Nou *et al.*, 1995) and the CRP site. The 327 bp DNA fragment used as a probe in Fig. 7 is also shown. The scale shown at the bottom is relative to the *papBA* transcription start site.

B. Electrophoretic mobility shift analysis (EMSA) was carried out as described in *Experimental procedures* using 0.5 µ.g of plasmid pDAL337 digested with *Eco*RI, *Bst*BI, *Apal* and *Bg*/II (see A). The sizes of DNA restriction fragments are shown at the left with the arrow indicating DNA fragments containing the *pap* regulatory region. Purified H-NS was added at the concentrations shown at the top.

block methylation of the pap GATC sites by Dam, H-NS was added to the 327 bp pap DNA before incubation with Dam (Fig. 7A, lanes 4-8). Results showed that H-NS blocked methylation of both the pap GATC-I and GATC-II sites as evidenced by the presence of 125 bp and 223 bp DNA fragments respectively (Fig. 7A). A parallel mobility shift analysis showed that, although all of the pap probe was in complex with H-NS at 0.7 µM H-NS, no methylation protection occurred (Fig. 7B). Doubling the H-NS level resulted in a slower moving protein-DNA complex, and maximal methylation protection was observed. As the H-NS level was increased, the mobility of H-NS-pap DNA complexes appeared to be slightly reduced, and methylation of the pap GATC sites was not inhibited (Fig. 7). These results showed that H-NS blocked methylation of the pap GATC sites in vitro and suggested that this activity was caused by specific binding of H-NS, as methylation protection was observed at low levels of H-NS at which binding was specific but not at higher H-NS levels at which non-specific binding occurred (Fig. 6B).

#### Temperature-dependent repression of pap transcription occurs within one cell generation

To understand further the mechanism by which *pap* thermoregulation occurred, *papB* mRNA levels,  $\beta$ -galactosidase levels and the percentage of bacteria remaining in the phase ON DNA methylation state were measured in wild-type strain DL1504 after a temperature shift from 37°C to 23°C. During the first generation of growth at 23°C, *papB* mRNA levels initially increased fourfold compared with the amount of mRNA present in the initial 37°C culture (Fig. 8A). Measurement of the half-life ( $t_{1/2}$ ) of *papB* mRNA at 23°C after rifampicin addition demonstrated that the  $t_{1/2}$  was increased fivefold at 23°C ( $t_{1/2} = 4 \text{ min}$ ) compared with 37°C ( $t_{1/2} = 45 \text{ s}$ ) (Fig. 9), which could account for the initial increase in *papB* mRNA observed at 23°C, assuming a constant mRNA synthesis rate. By the end of the first generation of growth at 23°C, *papB* mRNA was not detectable, indicating that transcription initiated at the *papBAp* promoter was totally shut off (Fig. 8A).

Concurrent with the measurement of *papB* mRNA,  $\beta$ -galactosidase activity was also monitored at each time point following the temperature shift to 23°C. Initially, the  $\beta$ -galactosidase activity increased about twofold, then gradually decreased from the first generation through succeeding generations (Fig. 8B). By 10 generations of growth, the  $\beta$ -galactosidase level reflected the low level of *papB* mRNA present at 23°C (Fig. 8B). Notably, the rapid repression of *papB* transcription following a 37°C to 23°C shift, measured using an RNase protection assay (Fig. 8A), was not observed using  $\beta$ -galactosidase activity as a measure of *papBA* transcription (Fig. 8B). Presumably, this discrepancy in results was caused by a higher stability of  $\beta$ -galactosidase than *papB* mRNA at 23°C.

At 37°C, the fraction of cells containing a non-methylated *pap* GATC-I site is a direct measure of the fraction of cells in the phase ON transcription state. Conversely, the fraction of cells with a non-methylated *pap* GATC-II



Fig. 7. In vitro DNA methylation protection analysis.

A. H-NS at the concentrations indicated was incubated with <sup>32</sup>P-labelled *pap* regulatory DNA (0.49 nM of the 327 bp DNA fragment shown in Fig. 6A) for 20 min at 23°C. Dam (0.8 units) was added (+) or not added (0) for 30 min, and samples were prepared for restriction digestion with *Mbol* and analysed on a 4% acrylamide gel as described in *Experimental procedures*. The locations of the 327 bp ('uncut') *pap* regulatory DNA and *pap* DNA fragments resulting from *Mbol* digestion at GATC-II and GATC-I are shown on the left. Quantitation of each lane of the acrylamide gel is shown lined up directly below and is expressed as the percentage of *pap* GATC sites that were protected from Dam methylation by H-NS.

B. Electrophoretic mobility shift analysis was performed in parallel with the methylation protection analysis shown in (A) directly above as described in *Experimental procedures*.

site is a measure of the fraction of cells in the phase OFF transcription state (Nou *et al.*, 1995). Therefore, to determine the effect of the 37°C to 23°C temperature shift on *pap* phase variation, we measured the fraction of cellular

© 1998 Blackwell Science Ltd, Molecular Microbiology, 28, 1121-1137



**Fig. 8.** Temporal analysis of *papBA* mRNA levels and *pap* GATC methylation states after a 37°C to 23°C temperature downshift. Phase ON (Lac<sup>+</sup>) *E. coli* isolate DL1504 was grown in M9 glycerol medium at 37°C. Different dilutions were shifted to 23°C, and each diluted culture was grown to exponential phase (A<sub>600</sub> = 0.6), at which time DNA and RNA were isolated, and β-galactosidase expression was measured from the sample. The generation time at 23°C was approximately 4h.

A. *papB* mRNA was quantitated using an RNase I protection assay as described in *Experimental procedures*. The ordinate shows the percentage of *papB* mRNA present relative to the level measured at '0' time.

B. The level of  $\beta$ -galactosidase activity expressed from the *papBAp–lacZ* fusion was quantitated at different times. C. The percentage of *pap* DNAs containing a non-methylated *pap* GATC-I site (ON methylation state, open circles) or a nonmethylated GATC-II site (OFF methylation state, closed circles) is shown. DNA methylation analyses were carried out by digestion with *Mbo*I and Southern blotting (*Experimental procedures*).

DNA containing non-methylated GATC-I (ON state) and GATC-II sites (OFF state) by Southern blot analyses of *Mbo*I-digested *pap* DNAs. We observed a rapid decrease in methylation protection of the GATC-I site after a shift to



**Fig. 9.** Determination of *papB* mRNA half-lives at 23°C and 37°C. *E. coli* DL1504 was grown in M9 glycerol medium at 37°C to exponential phase, and one half of the culture was shifted to 23°C. After 20 min, rifampicin was added to each culture aliquot and, at different times, samples were taken for quantitation of *papB* mRNA as described in *Experimental procedures*.

23°C (Fig. 8C). This was probably caused by dissociation of Lrp from sites 4 and 5 in the GATC-I region (Braaten et al., 1991). The loss of methylation protection at GATC-I after a shift to 23°C was accompanied by a reciprocal increase in methylation protection at GATC-II (Fig. 8C). These results suggested that, after dissociation of Lrp from GATC-I, Lrp reassociated at GATC-II. Alternatively, it is possible that H-NS might also have bound at GATC-II, as H-NS blocked methylation of GATC-II at 23°C in the absence of Lrp (Fig. 4). In any case, a comparison of Fig. 8A and C shows that temperature-dependent repression of papBA transcription at 23°C involved more than just the transition of cells from the phase ON to phase OFF states. After one generation of growth at 23°C, papBA transcription was shut off (Fig. 8A), even though over 20% of cells remained in the phase ON state (Fig. 8C) Thus, transcription in these phase ON cells was shut off rapidly at 23°C preceding the transition to the phase OFF methylation state.

#### Discussion

The results presented here provide a framework for understanding the mechanism by which thermoregulation of *pap* gene expression occurs. Our data indicate that H-NS, which is required for Pap thermoregulation (Table 3; Göransson *et al.*, 1990), is a temperature-dependent DNA methylation blocking factor *in vivo*, inhibiting methylation of the *pap* regulatory DNA GATC sites at 23°C but not 37°C (Fig. 4). H-NS could block the methylation of the *pap* GATC sites directly by binding to *pap* regulatory DNA or indirectly via the regulation of another DNA binding protein. We favour the former hypothesis, as our results showed that H-NS bound specifically to pap regulatory DNA containing the GATC-I and GATC-II sites (Fig. 6B) and blocked methylation of these sites by Dam in vitro (Fig. 7). These data raise the possibility that H-NS blocked pap transcription by competing with and/or altering the binding of Lrp with pap DNA, which includes the GATC-I and GATC-II sites. H-NS could act as a transcriptional repressor by inhibiting papBAp activation that results from binding of Lrp to sites 4 and 5 (Braaten et al., 1994; Nou et al., 1995). H-NS might also stabilize the phase OFF transcription state by interacting with Lrp bound at sites 1, 2 and 3 (van der Woude et al., 1996; see Fig. 6A). Alternatively H-NS could alter the interaction of RNA polymerase with the papBAp promoter as was recently suggested for bgl repression (Mizuno et al., 1996).

Based on the results shown here, it is likely that a key step in repressing pap transcription in response to a temperature downshift is the temperature-dependent alteration of binding of H-NS to pap regulatory DNA, observed as an increase in methylation protection of the pap GATC-I and GATC-II sites (Fig. 4). Previous data indicated that H-NS levels were transiently increased about fourfold in response to a temperature downshift from 37°C to 10°C (LaTeana et al., 1991). However, our results showed that H-NS levels were similar at 23°C and 30°C (Fig. 5) and thus could not account for the alteration in H-NS binding observed. It is also possible that H-NS-mediated methylation protection requires a co-factor that is active only at 23°C. However, this does not seems likely, as purified H-NS protected methylation of the GATC sites in the absence of other factors (Fig. 6B). A third possibility that we favour is that the conformation of H-NS is altered by temperature. This could occur directly as an intrinsic property of H-NS or indirectly by a temperature-dependent modification of H-NS. Previous results using isoelectric focusing showed that a number of isoforms were present (Spassky et al., 1984; Ussery et al., 1994), although the role(s) of these isoforms in H-NS function is not known. These possibilities can be addressed by determining if H-NS blocks methylation of the pap GATC sites at 37°C in vitro (the results shown in Fig. 6 were obtained at 23°C) and if the relative levels of different H-NS isoforms are altered at 23°C compared with 37°C.

Although H-NS blocked methylation of the *pap* GATC sites *in vitro* at 23°C, it did so only at low concentrations at which specific binding was observed but not at higher concentrations at which H-NS bound non-specifically (Figs 6 and 7). These results are consistent with previous observations indicating that the complexes formed between H-NS and specific DNA sites are distinguishable from complexes formed between H-NS and non-specific sites (Tippner and Wagner, 1995). Recently, it has been shown that oligomerization of H-NS is required for binding to

specific but not non-specific DNA binding sites and for bending of non-curved DNA (Spurio *et al.*, 1997). Binding of H-NS to the AT-rich DNA sequences that adjoin the *pap* GATC-I (GATCTTTAT) and GATC-II sites (TTAAAA-GATC) may aid the formation of multimeric protein–DNA complexes that sequester the GATC sites and prevent Dam methylation. Higher levels of H-NS that result in occupancy of non-specific *pap* DNA binding sites might further alter DNA conformation and disrupt H-NS interactions, allowing Dam access to the GATC sites. A prediction of this model is that H-NS lacking the ability to oligomerize (but retaining DNA binding activity) would be unable to block *pap* GATC methylation.

Temporal analysis of papB mRNA levels following a 37°C to 23°C downshift showed that pap transcription was shut off within one cell generation (Fig. 8A). However, after one cell generation, a significant fraction of cells (about 20%) remained in the phase ON methylation state (Fig. 8C). Thus, although H-NS increased the phase ON to phase OFF rate at 23°C, it must also have shut off transcription from the papBAp promoter in the phase ON cells remaining in the first generation following a shiftdown from 37°C to 23°C. Previously, it was hypothesized that thermoregulation of papBA transcription was caused by limiting amounts of PapI at low temperature. Based on Northern blot analysis, it was suggested Papl would be limiting because papl transcription was thermoregulated (Göransson et al., 1989a). As Papl is required to activate transcription from the papBAp promoter, a lack of PapI would lead to a loss of papBA transcription. Thus, the thermoregulation of papBA would simply be an indirect effect of the thermoregulation of papl transcription. This theory was supported by the observation that overproduction of Papl at low temperature caused a loss of thermoregulation (Göransson et al., 1989a). The data presented in this paper contradict this hypothesis. Using a constitutively expressed plasmid-encoded papl gene, we have shown that papBA transcription was reduced six- to eightfold at 23°C (Fig. 2B, DL3056 and DL2771) in the presence of a higher level of Papl than was present in cells in which papBA transcription occurred at 37°C (Fig. 2B, DL1504). Thus, the level of Papl did not correlate with thermoregulation of papBA transcription. Moreover, our data showed that papBA thermoregulation occurred in the absence of Papl (Fig. 2B, DL1742). Together, these results strongly indicated that papl does not play a direct role in the thermoregulation of papBA transcription.

Why is transcription from the *papIp* promoter thermoregulated? First, a reduction in transcription of *papBAp* would reduce *papIp* transcription indirectly via a decrease in the level of PapB, which is an activator of *papI* transcription (Forsman *et al.*, 1989). Secondly, our recent data indicate that transcription from the *papIp* and divergent *papBAp* promoters is dependent upon the same nucleoprotein complex organized by Lrp and CRP. Mutations that block binding of Lrp to the GATC-I region shut off both *papBAp* and *papIp* transcription (unpublished data). Thus, the temperature-dependent dissociation of Lrp from the GATC-I region observed by DNA methylation pattern analysis (Fig. 8C) would be expected to block both *papBAp* and *papIp* transcription.

Previous results have shown that mutations in Lrp binding site 3, adjacent to GATC-II, blocked papBA thermoregulation. These pap mutations resulted in a Papl-independent, phase-locked ON phenotype at both 37°C and 23°C (Nou et al., 1995). In contrast, a mutation in GATC-I (GCTC-I) was also locked ON and Papl-independent (DL1505, Fig. 2B) but could still thermoregulate (phase-locked ON at 37°C and transcriptionally inactive at 23°C). Why do these two pap mutations result in different thermoregulatory phenotypes? One possibility is that specific binding of H-NS to pap DNA at 23°C might stabilize the phase OFF state by interaction with Lrp bound at sites 1, 2 and 3 around GATC-II (discussed above). Mutation of site 3 would counteract this stabilization by reducing Lrp affinity for pap sites 1, 2 and 3, which are highly co-operative (Nou et al., 1995), allowing formation of the phase ON state in which Lrp binds to sites 4, 5 and 6. An alternative hypothesis raised by the results presented here is that DNA sequences within Lrp site 3 (CATAAAAAAC) may also serve as an H-NS binding site critical for H-NS-mediated repression. According to either of these hypotheses, the GCTC-I mutant would maintain its thermoregulatory response because Lrp and H-NS could still interact near the unaltered GATC-II region to shut off pap transcription. These hypotheses are being tested.

In Salmonella typhimurium, the proU operon, like the pap operon, is controlled by H-NS. H-NS represses transcription of the proU operon under conditions of low osmolarity (Higgins et al., 1988; Dattananda et al., 1991; Lucht and Bremer, 1991). A DNA region involved in the repression of proU transcription was identified downstream of the proU promoter at nucleotide positions +73 to +274within the coding region of the first gene of the operon (Fletcher and Czonka, 1995). H-NS has been shown to bind to the AT-rich DNA flanking the E. coli proU promoter, with a strong binding site between positions +60 and +110 (Lucht et al., 1994), in good agreement with the DNA region involved in proU repression localized in S. typhimurium (Fletcher and Czonka, 1995). These data are consistent with the hypothesis that H-NS binds to a region within the proU operon to repress transcription from the *proU* promoter. The results presented here show that a DNA sequence required for temperature-dependent repression of papBA transcription is located within and/or adjacent to the papB coding sequence, although the PapB protein was not required for papBA thermoregulation (Figs 1 and 3). The role of this *cis*-acting *papB* DNA in

#### 1134 C. A. White-Ziegler et al.

thermoregulation is not clear. Results in Fig. 6B indicated that the affinity of H-NS for *papB* DNA (543 bp DNA fragment) was lower than for *pap* regulatory DNA (363 bp DNA fragment). However, it is still possible that binding of H-NS to a region of this DNA (defined by deletion  $\Delta$ B59, Fig. 1) is required for thermoregulation. Further mutational analyses will need to be carried out to determine the exact *pap* DNA sequence required for thermoregulation and its function.

#### **Experimental procedures**

#### Bacterial strains, plasmids, bacteriophage and media

The strains, plasmids and bacteriophage used in this study are shown in Table 1. Luria–Bertani (LB) broth, LB agar, M9 minimal (M9) broth and M9 agar were prepared according to Miller (1972). The carbon source used in M9 media was glycerol at a final concentration of 0.2%. Casamino acids, when used, were at a final concentration of 0.2%. Antibiotics, when used, were at the following final concentrations: kanamycin,  $25 \,\mu g \,ml^{-1}$ ; ampicillin,  $100 \,\mu g \,ml^{-1}$ ; tetracycline,  $12.5 \,\mu g \,ml^{-1}$ ; and chloramphenicol,  $34 \,\mu g \,ml^{-1}$ . The chromogenic substrate 5-bromo-4-chloro-3-indolyl-β-D-galactoside (Xgal; Gold Biotechnology) was used at a final concentration of  $40 \,\mu g \,ml^{-1}$  of M9 agar medium.

Plasmid pDAL468 contains a 271 bp fragment encoding the *papl* gene cloned into the vector pACYC184 and constitutively expresses Papl. To construct plasmid pDAL468, plasmid pDAL262 was cut with *Taq*1, end filled with Klenow enzyme and subsequently digested with the restriction enzyme *Sphl*. The 271 bp fragment containing *papl* was isolated and ligated into *Eco*RV–*Sphl*-digested pACYC184. The resulting plasmid pDAL468 is chloramphenicol resistant.

#### Construction of pap mutant derivatives

Each of the following *pap* derivatives was constructed using the plasmids designated below. Each *pap* DNA sequence was recombined onto phage  $\lambda$ RS45, integrated into the *E. coli* chromosome, and single-copy lysogens were used for analysis as described previously (Simons *et al.*, 1987; Braaten *et al.*, 1994).

Plasmid pDAL491, containing a papIp-lacZ transcription fusion, was constructed by introducing a SphI site into the multiple cloning site of plasmid pRS551 (Simons et al., 1987) to construct pDAL485. A 1176 bp EcoRI-SphI pap DNA fragment containing the papl and papB genes was ligated into EcoRI-SphI-digested pDAL485 to construct pDAL491. On this plasmid, the papl rho-dependent terminator site has been removed, allowing the paplp promoter to drive lacZ transcription. Plasmid pDAL354 contains a 1.76 kb papIB regulatory sequence with the papBAp promoter controlling lacZ transcription (Nou et al., 1995). Plasmid pDAL354-15 has an A to C transversion mutation within the start codon of *papB*, changing ATG to CTG. Plasmid pDAL354-59 contains a 503 bp deletion of the pap sequence from bp 1222 to bp 1720 (see Fig. 1). Plasmid pDAL354-73 contains a 2 bp insertion frameshift mutation, 5'-TG-3', between pap base 806 and 807 of *papI*, resulting in a nearby translational stop site. The  $\Delta papI$  mutation in *E. coli* DL1742 was constructed as described previously (Nou *et al.*, 1995).

#### Calculation of switch frequencies

Pap phase switch frequencies were calculated as described previously (Blyn *et al.*, 1989) and are based on data from two to three separate colonies.

#### Measurement of $\beta$ -galactosidase activity

Each bacterial strain was inoculated from a frozen  $-70^{\circ}$ C stock onto M9 agar containing glycerol, incubated at  $37^{\circ}$ C and passed once on M9 agar. After growth for 36 h, a Lac<sup>+</sup> colony (a Lac<sup>-</sup> colony from those strains that did not express any Lac<sup>+</sup> colonies) was isolated and resuspended in 1 ml of M9 salts. Two flasks containing 15 ml of prewarmed M9 broth with glycerol were inoculated with 100  $\mu$ l of the colony suspension and incubated at either 37°C or 23°C in a shaking water bath. The cultures were grown to log phase (OD<sub>600</sub> = 0.25–0.9), and β-galactosidase activities were measured as described previously (Miller, 1972). This inoculation method ensured that all strains had grown for 9–11 generations at either 37°C or 23°C before β-galactosidase measurements. All β-galactosidase activities were an average from two or more separate cultures grown under identical conditions.

### Bacterial chromosomal DNA isolation and Southern analysis

Bacteria were collected from cultures grown as described under the measurement of  $\beta$ -galactosidase activities (see above) with the exception of the temperature downshift experiment (see below). Chromosomal DNAs were isolated as described previously (Ausubel *et al.*, 1987), digested with the appropriate restriction enzymes and analysed on a 1.2% agarose gel. The separated DNA fragments were subsequently transferred and cross-linked to Hybond-N membrane (Amersham) using Stratagene's Posiblot system and the UV Stratalinker 1800.

The Southern blot analysis shown in Fig. 4 was performed using a 1.76 kb *Eco*RI <sup>32</sup>P-labelled *pap* DNA fragment (see Fig. 1, bp 1–1760). The temperature downshift experiment (Fig. 8C) was carried out using an 80 bp <sup>32</sup>P-labelled DNA fragment derived from the inter-GATC-I/GATC-II *pap* DNA region (Fig. 1). Quantitation of the fraction of *pap* DNAs in the phase ON or phase OFF states was carried out by phosphorimager analysis (Bio-Rad Phosphoranalyst) or film densitometry.

#### Antibody production to GST-H-NS fusion protein

The *hns* gene was cloned into plasmid pGEX-2T (Pharmacia Biotech). Plasmid pGEX-2T contains coding sequences for glutathione-*S*-transferase (GST) and a thrombin cleavage site. For protein expression, the plasmid construct containing *hns-gst* (pDAL481) was transformed into the bacterial strain UT5600 constructing DL2754 (Table 1).

Expression of recombinant GST–H-NS protein was carried out by inducing cells in log phase with IPTG (0.5 mM). Bacteria were harvested by centrifugation, washed once in phosphatebuffered saline, pH7.4 (PBS), and resuspended in 5 ml of PBS containing protease inhibitors (pepstatin A, 1  $\mu$ g ml<sup>-1</sup>; antipain, 1  $\mu$ g ml<sup>-1</sup>; leupeptin, 1  $\mu$ g ml<sup>-1</sup>; chymostatin, 1  $\mu$ g ml<sup>-1</sup>; and phenylmethylsulphonyl fluoride, 10  $\mu$ g ml<sup>-1</sup>). The bacterial cells were broken by sonication, Triton X-100 was added to 1% final concentration, and the extract was clarified by centrifugation. Glycerol was added to the supernatant to a final concentration of 10%, and the extract was frozen at  $-70^{\circ}$ C.

The GST–H-NS fusion protein was isolated using glutathione–agarose beads (Sigma). Elution was carried out using a reduced glutathione buffer (10 mM in 50 mM Tris, pH 8.0). Immunoblot analysis showed that the GST–H-NS fusion protein was of the predicted size of 42 kDa (26 kDa GST plus 16 kDa H-NS). Antiserum against the GST–H-NS fusion protein was raised in rabbits (Cocalico Biologicals).

#### Immunoblotting

The immunoblot analyses shown in Figs 2 and 5 were performed as described previously (Harlow and Lane, 1988). Briefly, equal amounts of total cellular protein were analysed using SDS–PAGE. Proteins were transferred to nitrocellulose (Costar) using a transblot electroblotter (Bio-Rad). Polyclonal antisera to H-NS and Papl were adsorbed against total *E. coli* proteins bound to sepharose beads (Sambrook *et al.*, 1989). The H-NS antiserum was purified using beads coated with proteins from the *hns651* strain DL1976 (van der Woude *et al.*, 1995). Detection of H-NS and Papl was carried out using [<sup>125</sup>I]-protein A (Dupont NEN). Preflashed radiographic film was exposed to membranes containing radiolabelled proteins, and individual bands were quantitated using film densitometry (Bio-Rad).

#### H-NS purification

H-NS was purified from E. coli DL3317 (Table 1) containing plasmid pDAL569, which has hns under the control of the Plac/ara-1 promoter from plasmid pUHE2 PzI-2 (Lutz and Bujard, 1997). Plasmid pDAL569 was constructed as follows. A 411 bp DNA fragment encompassing the entire H-NS coding sequence was amplified from E. coli chromosomal DNA using an H-NS PCR primer with a KpnI site adjacent to the hns start codon (5'-CAACAAGGTACCATGAGCGAAGCACT-TAAAATTC-3') and a PCR primer with an Xbal site adjacent to the H-NS stop codon (5'-CAACAATCTAGATTATTGCTT-GATCAGGAAATCG-3'). The hns PCR product DNA and vector pUHE2 PzI-2 were digested with KpnI and XbaI. The appropriate DNA fragments were isolated from agarose gels, ligated and transformed into E. coli XL-2 Blue (Stratagene). DNA sequence analysis of the resulting plasmid pDAL569 showed that the hns DNA sequence was error-free. Two litres of DL3317 were grown at 37°C to an  $A_{600} = 0.8$ , and H-NS overexpression was induced by the addition of IPTG and arabinose (1 mM and 0.05% final concentrations respectively). After a 2h induction, cells were harvested by centrifugation and resuspended in 30 ml of PG buffer [50 mM sodium phosphate buffer, pH7.4 containing EGTA (1 mM), β-mercaptoethanol (10 mM), phenylmethylsulphonyl fluoride (PMSF; 1 mM) and glycerol (2%)]. This and all subsequent steps were carried out at 4°C. Bacteria were broken by passage through a French pressure cell at 18 000 p.s.i., and cell debris was separated by centrifugation at  $22\,000 \times g$  for 1 h. After bringing the volume to 60 ml by the addition of PG buffer, cell lysate was loaded onto a phosphocellulose P-11 column (30 ml bed volume) and eluted with a 0–1.0 M NaCl linear gradient (300 ml). Fractions eluting at 0.35–0.45 M NaCl contained H-NS and were dialysed against TN buffer (10 mM Tris HCl, pH 8.0, 0.1 M NaCl, 1 mM  $\beta$ -mercaptoethanol) using 3 kDa cut-off dialysis membranes (Spectrapor). Final purification was carried out by FPLC on a mono-Q 5/5 column (Pharmacia LKB) equilibrated in TN buffer with elution by a 0.1–1.0 M NaCl linear gradient (5 ml). H-NS eluted as a sharp peak at 0.5 M NaCl and was judged to be 98% pure based on SDS–PAGE analysis.

### Competitive electrophoretic mobility shift assay (EMSA)

Purified H-NS (see above) was incubated with restrictiondigested *pap* plasmid pDAL337 (0.5 µg) in binding buffer (10 mM Tris HCI, pH7.5, 1 mM EDTA, 80 mM NaCI, 10 mM  $\beta$ -mercaptoethanol, 4% glycerol, 50 µg ml<sup>-1</sup> bovine serum albumin). After a 20 min incubation, protein–DNA complexes were separated on 4% acrylamide gels in 0.5×TBE buffer (45 mM Tris-borate, 1 mM EDTA). DNA was visualized by ethidium bromide staining.

#### In vitro methylation protection assay

The ability of H-NS to protect the pap GATC-I and GATC-II sites from methylation by Dam was determined using a 327 bp pap DNA probe containing Lrp binding sites 1-6 spanning bp -278 to +49 (see Fig. 6A). This 327 bp pap DNA was amplified by polymerase chain reaction (PCR) using <sup>32</sup>P-end-labelled oligonucleotide 5'-CTCTATGTTT-GCTTTATTTGTTC-3' and non-labelled oligonucleotide 5'-CCCTTCTGTCGGGCCCC-3' with plasmid pDAL337 DNA template. H-NS was incubated with radiolabelled pap DNA (0.49 nM) in binding buffer (see above) containing 80 µM Sadenosyl methionine (SAM) for 20 min at 23°C. Dam (0.8 units) was then added for 30 min followed by a 10 min incubation at 65°C to inactivate Dam. H-NS, which is heat stable, was removed by phenol extraction. Residual phenol was removed by centrifugation using Micro Biospin-30 columns (Bio-Rad), and DNAs were digested with restriction endonuclease Mbol, which cuts at non-methylated GATC sites. DNA analysis was carried out using 4% acrylamide gels in 0.5×TBE buffer (above) followed by autoradiography (see Fig. 7A). A parallel EMSA experiment was carried out by incubating H-NS with radiolabelled 327 bp pap DNA for 20 min as described above for methylation protection and analysis on 4% acrylamide/TBE gels (see Fig. 7B). Quantitation of the fraction of DNAs protected from methylation was performed using phosphorimager analysis (Bio-Rad).

#### Ribonuclease protection assay

The RNA probes used for ribonuclease protection were synthesized *in vitro* using DNA templates constructed by PCR. The 5' end of the *papB* gene was amplified by PCR from chromosomal

#### 1136 C. A. White-Ziegler et al.

DNA of strain DL1504 (Table 1) using oligonucleotide primer 5'-CGGAATTCGCCATGATGTTTTTATCTGAGTACC-3' and oligonucleotide5'-CTGGATCCTAATACGACTCACTATAGG-GAGGCTCCTTACGGGAGTGCC-3', which contains a phage T7 RNA polymerase promoter at the 3' end to allow production of the antisense RNA by phage T7 RNA polymerase. Similarly, the 5' end of the murF gene was amplified by PCR using oligonucleotide 5'-CGGAATTCATGATTAGCGTAACCCTT-A-3' and oligonucleotide 5'-CTGGATCCTAATACGACTCA-CTATAGGGAGGGGGGGGGGATATCTGCACCTT-3' containing a T7 RNA polymerase promoter at the 3' end. Antisense RNA probes were labelled with  $[\alpha^{-32}P]$ -UTP by *in vitro* transcription using T7 RNA polymerase (Ambion). The murF RNA probe was used as an internal control, as similar levels of transcript are expressed at both 37°C and 23°C (data not shown). Full-length RNA probes from in vitro transcription reactions were isolated by electrophoresis in a 6% acrylamide gel.

Ribonuclease protection assays were performed using the RPA II kit (Ambion). For each time point, 1.25  $\mu$ g of total cellular RNA, isolated as described previously (Hagen and Young, 1978), was used, and both the radiolabelled *papB* and *murF* probes were added to each RNA sample in molar excess. RNA samples were separated by electrophoresis (8% acrylamide), preflashed radiographic film was exposed to the gel and bands were quantitated by densitometry. The *papB* mRNA levels were quantitated and corrected for differences in sample load using the *murF* as an internal control.

#### Measurement of papB mRNA half-lives

To determine the half-lives of the 5' end of the *papB* mRNA at 23°C and 37°C, bacterial cultures were grown at 37°C to midlog phase and divided into two flasks. One flask was incubated at 37°C and the other at 23°C. Rifampicin ( $20 \text{ mg ml}^{-1}$  in methanol) was added to a final concentration of  $200 \text{ }\mu\text{g} \text{ ml}^{-1}$  to both flasks after a 20 min preincubation. Aliquots of 5 ml were removed at various time points for RNA isolation. Levels of *papB* RNA were quantitated as described above using the ribonuclease protection assay.

#### Acknowledgements

We thank N. Patrick Higgins and Chris Higgins for generous gifts of H-NS antisera and bacterial strains; Arjen Brinkman and Linda Kaltenbach for their help in plasmid constructs; Chiharu Ueguchi for plasmid pHOP11 (which served as a control for H-NS expression); and the Protein–DNA Core Facility, Cancer Center, University of Utah, Salt Lake City, UT, USA, for the production of oligonucleotides used in this study. The facility is supported by National Cancer Institute Grant 5P30-CA42014-07. This work was supported by National Institutes of Health Grant GM45379 to D.A.L.

#### References

- Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A., *et al.* (1987) *Current Protocols in Molecular Biology*. New York: Wiley.
- Båga, M., Göransson, M., Normark, S., and Uhlin, B.E.

(1985) Transcriptional activation of a *pap* pilus virulence operon from uropathogenic *Escherichia coli*. *EMBO J* **4**: 3887–3893.

- Blyn, L.B., Braaten, B.A., White-Ziegler, C.A., Rolfson, D.H., and Low, D.A. (1989) Phase-variation of pyelonephritisassociated pili in *Escherichia coli*: evidence for transcriptional regulation. *EMBO J* 8: 613–620.
- Blyn, L.B., Braaten, B.A., and Low, D.A. (1990) Regulation of *pap* pilin phase variation by a mechanism involving differential Dam methylation states. *EMBO J* **9:** 4045– 4054.
- Braaten, B.A., Blyn, L.B., Skinner, B.S., and Low, D.A. (1991) Evidence for a methylation-blocking factor (*mbf*) locus involved in *pap* pilus expression and phase variation in *Escherichia coli*. *J Bacteriol* **173**: 1789–1800.
- Braaten, B.A., Nou, X., Kaltenbach, L.S., and Low, D.A. (1994) Methylation patterns in *pap* regulatory DNA control pyelonephritis-associated pili phase variation in *E. coli*. *Cell* **76**: 577–588.
- Calvo, J.M., and Matthews, R.G. (1994) The leucine-responsive regulatory protein (Lrp), a global regulator of metabolism in *Escherichia coli. Microbiol Rev* **58**: 466–490.
- Casadaban, M. (1976) Transposition and fusion of the *lac* genes to selected promoters in *E. coli* using bacteriophage lambda and Mu. *J Mol Biol* **104**: 541–555.
- Chang, F.N. (1978) Temperature-dependent variation in the extent of methylation of ribosomal proteins L7 and L12 in *Escherichia coli. J Bacteriol* **135**: 1165–1166.
- Coote, J.G. (1991) Antigenic switching and pathogenicity: environmental effects on virulence gene expression in *Bordetella pertussis. J Gen Microbiol* **137:** 2493–2503.
- Cornelis, G.R., Biot, T., Lambert de Rouvroit, C., Michiels, T., Mulder, B., Sluiters, C., *et al.* (1989) The *Yersinia yop* regulon. *Mol Microbiol* **3:** 1455–1459.
- Dattananda, C.S., Rajkumari, K., and Gowrishankar, J. (1991) Multiple mechanisms contribute to osmotic inducibility of *proU* operon expression in *Escherichia coli*: demonstration of two osmoresponsive promoters and of a negative regulatory element within the first structural gene. *J Bacteriol* **173**: 7481–7490.
- Falconi, M., McGovern, V., Gualerzi, C., Hillyard, D., and Higgins, N.P. (1991) Mutations altering chromosomal protein H-NS induce mini-Mu transposition. *New Biol* 3: 615–625.
- Fletcher, S.A., and Czonka, L.N. (1995) Fine-structure deletion analysis of the transcriptional silencer of the *proU* operon of *Salmonella typhimurium*. J Bacteriol **177**: 4508–4513.
- Forsman, K., Göransson, M., and Uhlin, B.E. (1989) Autoregulation and multiple DNA interactions by a transcriptional regulatory protein in *E. coli* pili biogenesis. *EMBO* J 8: 1271–1277.
- Göransson, M., and Uhlin, B.E. (1984) Environmental temperature regulates transcription of a virulence pili operon in *E. coli. EMBO J* **3**: 2885–2888.
- Göransson, M., Forsman, K., and Uhlin, B.E. (1989a) Regulatory genes in the thermoregulation of *Escherichia coli* pili gene transcription. *Genes Dev* **3**: 123–130.
- Göransson, M., Forsman, K., Nilsson, P., and Uhlin, B.E. (1989b) Upstream activating sequences that are shared by two divergently transcribed operons mediate cAMP-

<sup>© 1998</sup> Blackwell Science Ltd, Molecular Microbiology, 28, 1121-1137

CRP regulation of a pilus-adhesin is *Escherichia coli*. *Mol Microbiol* **3**: 1557–1565.

- Göransson, M., Sonden, B., Nilsson, P., Dagberg, B., Forsman, K., Emanuelsson, K., *et al.* (1990) Transcriptional silencing and thermoregulation of gene expression in *Escherichia coli. Nature* **344:** 682–685.
- Hagberg, L., Hull, R., Hull, S., Falkow, S., Freter, R., and Svanborg-Eden, C. (1983) Contribution of adhesion and bacterial persistence in the mouse urinary tract. *Infect Immun* **40**: 265–272.
- Hagen, F.S., and Young, E.T. (1978) Effect of RNase III on efficiency of translation of bacteriophage T7 lysozyme mRNA. *Virology* **26:** 793–804.
- Harlow, E., and Lane, D. (1988) *Antibodies. A Laboratory Manual.* Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
- Higgins, C.F., Dorman, C.J., Stirling, D.A., Waddell, L., Booth, I.R., May, G., *et al.* (1988) A physiological role for DNA supercoiling in the osmotic regulation of gene expression in *S. typhimurium* and *E. coli. Cell* **52**: 569–584.
- Jordi, B.J.A.M., Dagberg, B., deHaan, L.A.M., Hamers, A.M., vanderZeijst, B.A.M., Gasstra, W., *et al.* (1992) The positive regulator cfaD overcomes the repression mediated by histone-like protein H-NS (H1) in the CFA/I fimbrial operon of *Escherichia coli. EMBO J* **11**: 2627–2632.
- LaTeana, A., Brandi, A., Falconi, M., Spurio, R., Pon, C.L., and Gualerzi, C.O. (1991) Identification of a cold shock transcriptional enhancer of the *Escherichia coli* gene encoding nucleoid protein H-NS. *Proc Natl Acad Sci USA* **88**: 10907–10911.
- Leimeister, M., Domann, E., and Chakraborty, T. (1992) The expression of virulence genes in *Listeria monocytogenes* is thermoregulated. *J Bacteriol* **174**: 947–952.
- Lindberg, F.P., Lund, B., and Normark, S. (1984) Genes of pyelonephritogenic *E. coli* required for digalactosidase-specific agglutination of human cells. *EMBO J* **3**: 1167–1173.
- Low, D.A., Robinson, Jr, E.N., McGee, Z.A., and Falkow, S. (1987) The frequency of expression of pyelonephritisassociated pili is under regulatory control. *Mol Microbiol* **1**: 335–346.
- Lucht, J.M., and Bremer, E. (1991) Characterization of mutations affecting the osmoregulated *proU* promoter of *Escherichia coli* and identification of 5' sequences required for high-level expression. *J Bacteriol* **173**: 801–809.
- Lucht, J.M., Dersch, P., Kempf, B., and Bremer, E. (1994) Interactions of the nucleoid-associated DNA-binding protein H-NS with the regulatory region of the osmotically controlled *proU* operon of *Escherichia coli*. *J Biol Chem* **269**: 6578–6586.
- Lutz, R., and Bujard, H. (1997) Independent and tight regulation of transcriptional units in *Escherichia coli* via the LacR/ O and TetR/O and AraC/I1-I2 regulatory elements. *Nucleic Acids Res* **25**: 1203–1210.
- Maurelli, A.T., Blackmon, B., and Curtis, III, R. (1984) Temperature-dependent expression of virulence genes in *Shigella* species. *Infect Immun* **43**: 195–201.
- Miller, J.H. (1972) *Experiments in Molecular Genetics* Cold Spring Harbor, NY: Cold Spring Laboratory Press.
- Mizuno, U., Suzuki, T., Yoshida, T., Tanaka, K., and Mizuno, T. (1996) Systematic mutational analysis revealing the functional domain organization of *Escherichia coli* nucleoid protein H-NS. *J Mol Biol* **263**: 149–162.
- © 1998 Blackwell Science Ltd, Molecular Microbiology, 28, 1121-1137

- Nou, X., Skinner, B., Braaten, B., Blyn, L., Hirsh, D., and Low, D. (1993) Regulation of pyelonephritis-associated pili phase variation in *Escherichia coli*: binding of the Papl and Lrp regulatory proteins is controlled by DNA methylation. *Mol Microbiol* **7**: 545–553.
- Nou, X., Braaten, B., Kaltenbach, L., and Low, D.A. (1995) Differential binding of Lrp to two sets of *pap* DNA binding sites mediated by PapI regulates Pap phase variation in *Escherichia coli. EMBO J* **14:** 5785–5795.
- Roberts, J.A., Kaack, M.B., and Fussell, E.N. (1989) Bacterial adherence in urinary tract infections: preliminary studies in a primate model. *Infection* **17**: 401–404.
- Roosendaal, B., vanBergenen-Henegouwen, P.M.P., and deGraff, F.K. (1986) Subcellular localization of K99 fimbrial subunits and effect of temperature on subunit synthesis and assembly. *J Bacteriol* **165**: 1029–1032.
- Rupprecht, K.R., Gordon, G., Lundrigan, M., Gayda, R.C., Markovitz, A., and Earhart, C. (1983) OmpT: *Escherichia coli* K-12 structural gene for protein a (3b). *J Bacteriol* **153**: 1104–1106.
- Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989) *Molecular Cloning. A Laboratory Manual*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
- Simons, R.W., Houman, F., and Kleckner, N. (1987) Improved single and multicopy *lac*-based cloning vectors for protein and operon fusions. *Gene* **53**: 85–96.
- Spassky, A., Rimsky, S., Garreau, H., and Buc, H. (1984) H1a, an *E. coli* DNA-binding protein which accumulates in stationary phase, strongly compacts DNA *in vitro*. *Nucleic Acids Res* **12**: 5321–5340.
- Spurio, R., Falconi, M., Brandi, A., Pon, C., and Gualerzi, C. (1997) The oligomeric structure of nucleoid protein H-NS is necessary for recognition of intrinsically curved DNA and for DNA bending. *EMBO J* 16: 1795–1805.
- Tippner, D., and Wagner, R. (1995) Fluorescence analysis of the *Escherichia coli* transcription regulator H-NS reveals two distinguishable complexes dependent on binding to specific or non-specific DNA sites. *J Biol Chem* 270: 22243–22247.
- Ussery, D.W., Hinton, J.C.D., Jordi, B.J.A.M., Granum, P.E., Seirafi, A., Stephen, R.J., *et al.* (1994) The chromatinassociated protein H-NS. *Biochimie* **76**: 968–980.
- van der Woude, M.W., Braaten, B.A., and Low, D.A. (1992) Evidence for global regulatory control of pilus expression in *Escherichia coli* by Lrp and DNA methylation: model building based on analysis of *pap. Mol Microbiol* **6**: 2429–2435.
- van der Woude, M., Kaltenbach, L.S., and Low, D.A. (1995) Leucine-responsive regulatory protein plays dual roles as both an activator and a repressor of the *Escherichia coli pap* operon. *Mol Microbiol* **17:** 303–312.
- van der Woude, M., Braaten, B., and Low, D. (1996) Epigenetic phase variation of the *pap* operon in *Escherichia coli. Trends Microbiol* **4:** 5–9.
- White-Ziegler, C.A., Blyn, L.B., Braaten, B.A., and Low, D.A. (1990) Identification of a genetic locus in *Escherichia coli* involved in the thermoregulation of the *pap* operon. *J Bacteriol* **172**: 1775–1782.
- White-Ziegler, C.A., and Low, D.A. (1992) Thermoregulation of the *pap* operon: evidence for the involvement of RimJ, the N-terminal acetylase of ribosomal protein S5. *J Bacteriol* **174**: 7003–7012.